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Abstract 
 
The ICRP has published two biokinetic models providing a basis for radiation dose assessment due to 
radionuclides incorporated inside the gastrointestinal tract.  These models are a sufficient tool to assess 
the committed dose equivalent for occupational exposures to workers assuming normal anatomy.  The 
colostomy is becoming a more prevalent procedure.  A colostomy permanently or temporarily bypasses 
a portion of colon to allow rest and healing.  There are four different colostomies; ascending, transverse, 
descending and sigmoid and an ileostomy. As a patient’s strength returns, they can return to normal 
daily activities, including returning to work. Therefore, as an ostomy patient returns to the workforce 
handling radioactive material, the potential for exposure to the radioactive material for these workers 
increases.  The aim of this project is to determined whether or not an additional risk exists for these 
workers and if additional limitations should be placed on ostomy patients handling uranium. In order to 
determine if an additional risk exists two pathways are considered, ingestion and injection. Injection is a 
unique pathway for this work and is defined as radioactive material entering through the stoma.  As part 
of the injection scenario as well as in the event contamination occurs, the dose per hou to the stoma 
was also determined.  Using modified ICRP 30 gastrointestinal models and ICRP 100 HATM models to 
reflect the anatomy changes for each procedure, the committed dose equivalent (CDE) and committed 
effective dose equivalent (CEDE) was determined for each procedure.  In addition, using the more 
limiting value between the CDE and CEDE annual limit, the annual limit on intake (ALI) was determined.  
Based on a decrease in CDE values within the alimentary tract for each procedure and the determination 
the ALIs were either equivalent or orders of magnitude greater than the current ICRP ALI values no 
additional risk exists.  Finally, based on the dose per hour resulting from stoma contamination, the 
chemical hazards were determined to be of greater concern than the radiological. Therefore, no 
additional guidance is needed for ostomy patients working with uranium. 
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Key Terms 
 
Annual Limit on Intake  
 The activity of radionuclide, when taken alone, would irradiate a person to the limit set for 
 occupational exposure [1].  
Committed Dose Equivalent (HT,50)  
 The total dose equivalent in an organ or tissue after intake of a radionuclide into the body, 50 
 years for adults and 70 years for children [1]. 
Committed Effective Dose Equivalent 
 The committed dose equivalent weighted by the appropriate tissue weighting factor [1]. 
Equivalent dose 
 The absorbed dose multiplied by the appropriate quality factor [1]. 
Effective dose  
  The equivalent dose multiplied by the appropriate tissue weighting factor for a specified tissue 
Linear Energy Transfer 
 The amount of energy transferred by radiation to a medium per unit distance  
Tissue Weighting Factors 
 The ratio of the stochastic risk arising from tissue T to the risk when the whole body is uniformly 
 irradiated.  Table 1 displays the tissue weighting factors from ICRP 26, ICRP 60, and ICRP 103  
 [2][3][4]. 
  
 
 
xiii 
 
 
Table 1: Tissue weighting factors from ICRP 26, ICRP 60, and ICRP 103 
Tissue or Organ 
Tissue Weighting Factor 
ICRP 26 (1977) ICRP 60 (1990) ICRP 103 (2007) 
Bone Marrow (red) 0.12 0.12 0.12 
Breast 0.15 0.05 0.12 
Lung 0.12 0.12 0.12 
Stomach - 0.12 0.12 
Colon - 0.12 0.12 
Gonads 0.25 0.20 0.08 
Thyroid 0.03 0.05 0.04 
Bladder - 0.05 0.04 
Liver - 0.05 0.04 
Esophagus - 0.05 0.04 
Bone Surface 0.03 0.01 0.01 
Skin - 0.01 0.01 
Salivary Glands - - 0.01 
Brain - - 0.01 
Remainder 0.30 0.05 0.12 
 
Quality Factor/Radiation Weighting Factor 
 The modifying factor, dependent on the collision stopping power for charged particles, that is 
 used to determine equivalent dose from absorbed dose. This value is 20 for alpha particles and 1 
 for electrons [1]. 
1 
 
1.0 Introduction 
 
The ICRP has published several different biokinetic models providing a basis for radiation dose 
assessment due to radionuclides incorporated inside the human body. These models are sufficient tools 
to assess the committed dose equivalent for occupational exposures to workers assuming normal 
anatomy. A growing number of people have had a surgical procedure to remove either part of their 
intestine or  bypass a portion of their intestine. More specifically, these procedures include four 
different colostomies, ascending, transverse, descending and sigmoid and an ileostomy. Surgery may be 
required for various reasons including infection of the abdomen, injury to the colon or rectum, partial or 
total blockage of the large bowel, or rectal or colon cancer. Furthermore, a colostomy may be 
temporary or permanent depending on the extent of injury or disease. As a patient’s strength returns 
they can return to normal daily activities, including returning to work. In general, an ostomy patient is 
not limited in the job they can perform when they return [5].  Therefore, as an ostomy patient returning 
to the workforce handling radioactive material, the potential for exposure to the radioactive material for 
these workers increases.  
 
The ICRP models for the GI tract assumes a pathway through unmodified organs and tissues and does 
not take procedures such as these into consideration.  In addition, there is no guidance from the Nuclear 
Regulatory Commission (NRC) regarding restrictions on these workers, other than general guidance 
regarding open wound and potential injection risks. The NRC states intake through wounds and skin 
contamination must be evaluated and accounted for, when practical [1]. Therefore, it should be 
determined whether or not an additional risk exists for these workers, and if an increased risk does 
exist, what precautions need to be taken. This could include restrictions on the worker’s potential 
exposure to radioactive material to the development of guidance in case of contamination of the stoma, 
including the evaluation of what actions may be necessary to limit dose to the stoma and intestine itself.  
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To examine the potential risk for a worker with an ostomy, biokinetic models will be modified to reflect 
the new anatomy and estimate the dose to a worker with an ostomy following exposure to uranium. To 
determine the internal dose for workers dealing with uranium who have undergone an operation on 
their GI tract, the ICRP 30 and ICRP 100 biokinetic models can be modified to reflect the anatomical 
changes made by each surgery. Using the modified models, the dose to each organ can be determined 
as well as the total effective dose. The modified models will be used to investigate two different 
pathways, ingestion and injection.  Injection is a unique pathway proposed in this work for workers with 
an ostomy. Injection refers to the instantaneous injection of material through the stoma. While 
inhalation is also a pathway, it is not considered due to the small fraction of material transferred to the 
gastrointestinal tract from the inhalation pathway. By looking at the NRC reported annual limit of intake 
(ALI) for uranium, it can be determine whether or not a worker needs further limitations when working 
with uranium.  
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2.0 Background 
 
2.1 Internal Dosimetry 
 
Biokinetic models for internal exposure are used to determine the number of transformations occurring 
within an organ or tissue during a given period of time by determining  the  activity as a function of time 
in each source region. This time usually ranges from 50 years for adults and 70 years for children [2]. The 
model is used to calculate the number of transformations occurring in each region taking into account 
the energies and yields of all emissions.  Knowing the number of decays occurring in each organ and the 
energy deposited, the committed dose equivalent in sievert can be calculated.  
 
2.2 Dosimetry Principles 
 
To evaluate the dose to target tissues, the committed equivalent dose, HT, is determined.  The 
committed equivalent dose is determined by the number of nuclear transformations of a radionuclide 
within the source region, S, over a given period after intake of the radionuclide. In general, the period of 
time is 50 years for adults. In addition, HT is determined by the energy absorbed per mass in the target 
tissue, which is modified by the radiation weighting.  The radiation weighting factor is dependent upon 
the type of radiation emitted per nuclear transformation. The committed equivalent dose, HT, in the  
target tissue T can be expressed by Equation 1 [1].  
 
     𝐻𝑇 = 𝑐𝑈𝑠𝑆𝐸𝐸(𝑇 ← 𝑆)              (1) 
 
Where Us is the number of transformations of a radionuclide 50 years after intake, 𝑆𝐸𝐸(𝑇 ← 𝑆) is the 
specific effective energy per nuclear transformation in region S for a radionuclide and c taken to be 
1.6x10-13, the number of joules in one MeV, assuming SEE is in MeV per unit mass [1]. 
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For each radionuclide in the decay chain, the specific effective energy (SEE) at age t takes into account 
the contribution from each radiation emitted.  This is also weighted by the appropriate radiation 
weighting factor. The SEE can be determined by the following equation [1] 
 
  𝑆𝐸𝐸(𝑇 ← 𝑆)𝑖 =
∑ 𝑤𝑅,𝑖𝑌𝑖𝐸𝑖𝐴𝐹(𝑇←𝑆,𝐸𝑖,𝑡)+𝑤𝑅,𝛽 ∫ 𝑌(𝐸)𝐸𝐴𝐹(𝑇←𝑆,𝐸𝑖,𝑡)𝑑𝐸
∞
0
𝑀𝑇(𝑡)
           (2) 
 
 
Where, wr,I is the radiation weighting factor applicable to the i-th radiation, Yi is the intensity of the 
radiation, Ei is the energy of the i-th discrete radiation emitted by the radionuclide per nuclear 
transformation, MT(t) is the mass of the target tissue T at age t,  𝑨𝑭(𝑻 ← 𝑺, 𝑬𝒊, 𝒕) is the absorbed 
fraction quantity representing the fraction of the energy emitted in S that is absorbed in T for an 
individual of age t and Y(E) dE denotes the number of electrons in the beta or positron spectrum with 
energy between E and E + dE [1]. 
 
Each biokinetic model consists of multiple compartments corresponding to an individual organ. The 
translocation from consecutive compartments is governed by first order kinetics.  The solution gives the 
time dependent distribution of the radionuclide and its daughter, if applicable. If Ai,j(t) is the activity of 
the radionuclide i in compartment j at time, the number of nuclear transformations in a compartment is 
governed by the following first order differential equation [1]. 
 
  
𝑑𝐴𝑖,𝑗(𝑡)
𝑑𝑡
= ∑ 𝐴𝑖,𝑗𝜆𝑖,𝑘,𝑗 − 𝐴𝑖,𝑗[
𝑀
𝑘=1
𝑗≠𝑘
∑ 𝜆𝑖,𝑘,𝑗
𝑀
𝑘=1
𝑗≠𝑘
+ 𝜆𝑖
𝑝] ∑ 𝐴𝑘,𝑗𝛽𝑘,𝑖
𝑖−1
𝑘=1 𝜆𝑖
𝑝
          (3) 
 
Where:  
 
 M is the number of compartments describing the kinetics 
 
𝝀𝒊,𝒌,𝒋 is the fractional transfer rate, of chain member i from compartment j (donor 
compartment) to compartment k (receiving compartment). 
 
𝝀𝒊
𝒑
 is the decay constant of chain member i and  
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𝜷𝒌,𝒊 is the fraction of decays of chain member k forming member i.  
 
For example, using equation 3, the first compartment of the ICRP 30 gastrointestinal tract model, the 
stomach, the first order differential equation is given by equation  4 [1].  
 
    
𝑑
𝑑𝑡
𝑞𝑆𝑇 = −𝜆𝑆𝑇𝑞𝑆𝑇(𝑡) − 𝜆𝑅𝑞𝑆𝑇(𝑡) + 𝐼(𝑡)           (4) 
 
Where 
 
 I(t) is the rate of ingestion of a radionuclide 
 
 λST is the transfer coefficient of the stomach 
 
 λR is the decay constant of the radionuclide 
 
2.3 Annual Limit on Intake 
 
 
The current occupational exposure for ionizing radiation limit by the NRC is expressed as a total effective 
dose equivalent equal to 0.05 Sv or the committed equivalent dose to any organ other than the eye 
being equal to 0.5 Sv [6]. ICRP 60 updated recommendation to an intake of a radionuclide that would 
lead to a total effective dose of 0.02 Sv per year averaged over five years with the addition that the 
effective dose does not exceed 50 mSv in a year [2]. In the event skin contamination occurs, 
10CFR20.1201 limits shallow dose to the skin to 0.5 Sv to the skin of the whole body or to the skin of an 
extremity. The shallow dose must be averaged over the 10 cm2 receiving the highest exposure [6]. The 
annual dose limit applies to the sum of the effective doses from external radiation and the committed 
effective dose from intakes of radionuclides occurring within the one-year period [1].  In occupational 
exposure, doses are commonly received from external and internal sources.  For external exposures, 
individually monitoring is typically performed by measuring individual dose equivalents using personal 
dosimeters. On the other hand, for internal exposures, committed effective dose values are determined 
from bioassay samples or in the workplace. Internal exposure can also be described through the use of 
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dosimetric models for long periods of time. Calculated ALI are based solely on radiation dose and does 
not take into account the chemical effects [1].  
 
2.4 Skin Dose Calculation 
 
The NRC utilizes VARSKIN code, a tool used to assess doses from skin contamination. Varskin performs a 
five-dimensional integration of the source volume and the target area [7]. The mathematical kernel used 
calculate the dose by the code is 
 
     𝐵(𝑟) =
𝑘𝐸𝛽𝑌𝐹𝛽(
𝑟1
𝑋99
)
𝜋𝜌𝑟2𝑋99
     (5) 
 
Where: 
 
  r is the distance between the source point and the dose point 
 
 k is a unit conversion constant 
 
 Eβ is the average beta energy 
 
 Y is the  beta yield per disintegration 
 
 Fβ(r1/X99) is the scaled absorbed dose distribution  
 
 r1 is the modified path length between a source point and the dose point 
 
 ρ is the density of the material 
 
 
2.5 ICRP Publication 30 Dosimetric Model for the Gastrointestinal Tract  
 
The dosimetric model for the gastrointestinal tract provides an important tool for the determination of 
internal dose to a worker after ingestion of a radionuclide [1]. The model employs the same general 
method used to calculate H50,T. The methods used to calculate the number of transformations in the 
source organ, US, and H50 are discussed.  The gastrointestinal model breaks the system into separate 
sections and these sections are treated as separate target tissues. ICRP 30 breaks the colon into the 
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upper large intestine (ULI) and the lower large intestine (LLI). The ULI refers to the ascending and 
transverse colon and the LLI includes the descending, sigmoid colon, and rectrum. Figure 1 displays the 
different components that make up the GI tract dosimetric model from ingestion to excretion [1] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: ICRP 30 Gastrointestinal Tract Model 
 
Table 2: ICRP 30 transfer rates for each compartment of the GI tract model 
 
 
 
 
 
 
 
 
 
 
The value λB, corresponds to the transfer rate of material to the body fluids and can be estimated from 
f1, the fraction of a stable element that reaches the body fluids following ingestion [1].  
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      𝜆𝐵 =
𝑓1𝜆𝑆𝐼
1−𝑓1
     (6) 
 
The values of f1 are provided by metabolic data for various classes of compounds of individual isotopes. 
In addition, in the case of radioactive daughter isotopes the value of f1 is taken to be the stable isotope 
from which the ingested radionuclide is an isotope [1].  
 
      𝑓1 =
𝜆𝐵
𝜆𝑆𝐼+𝜆𝐵
     (7) 
 
In addition, absorption of ingested radioactivity is assumed to occur in the small intestine and can be 
described by element specific  “f1” values [1]. The f1 values represent fractional absorption of the stable 
element to the blood.   
 
Absorbed fractions estimations for beta and alpha particles due to the contents in the GI tract are 
assumed to be 1 and 0.01, respectively [1].  This is in addition to the dose to the walls of the GI tract 
from absorbed activity, particularly long-lived radionuclides. This is usually the dominant source of dose 
to the walls in the GI tract.  
 
2.6 ICRP 100 Human Alimentary Tract Model  
 
In 2006, the ICRP updated the ICRP 30 gastrointestinal tract model in ICRP publication 100. In 2015, the 
ICRP published ICRP publication 130 adopting the ICRP 100 HATM, formally replacing ICRP Publication 30 
gastrointestinal tract model [8]. This replacement of the ICRP 30 model was motivated by a number of 
developments including improved information on the gut transit of materials and the increased 
awareness of the location of sensitive cells [9]. The most important feature of the HATM is the 
calculation of doses to target regions containing sensitive cells for cancer induction [9].  The ICRP 100 
HATM also allows for retention  in alimentary tract walls and absorption to the blood from other areas 
within the GI tract.  One prominent difference between the ICRP30 model and the HATM is that the 
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HATM assumes a longer transit time through the alimentary tract and therefore a slower rate of fecal 
excretion for the first few days after ingestion of a radionuclide.   
 
Unlike the dosimetric model for the GI tract, the HATM also accounts for entrance into the esophagus 
after particle transport from the respiratory tract [9]. It describes the sequential transfer through all 
alimentary tract regions including the oral cavity, esophagus, stomach, the small intestine, and colon, 
followed by the excretion of feces. The doses are calculated for each region.  Based on the availability of 
transit time data, the colon is separated into right colon, left colon, rectosigmoid (the sigmoid colon and 
rectum) [9].  The sigmoid colon and the rectum are considered together because the transit times for 
each separately have not been determined and there is no specific WT value for the rectum.  The HATM 
and the ICRP 30 model yield similar tissue dose estimates for most radionuclides. However, in some 
cases the HATM will yield substantially different doses to walls of the alimentary tract due to the 
specification of retention of radionuclides in the walls of the tract and the explicit modeling of the 
sensitive cells of different regions of the GI tract in the HATM model [9]. The HATM is compatible with 
and inter-connected to the Human Respiratory Tract Model (HRTM) published in ICRP 66. Figure 2 
displays the HATM model [9]. 
 
The updated HATM is much more complex than the ICRP 30 GI tract model. The HATM depicts the entry 
of a radionuclide into the oral cavity through ingestion or into the esophagus following mechanical 
clearance from the respiratory tract.  In addition, the model also incorporates radionuclide deposition 
and retention on or between the teeth and return to the oral cavity and in the walls of the stomach and 
intestine, transfer from the walls of the stomach and the intestines back into luminal contents or the 
blood [9]. This process is referred to as absorption.  
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Figure 2: ICRP 100 Human Alimentary Tract Model 
 
 
The dashed boxes represent connection to organs with the respiratory tract model or systemic 
biokinetic model and are therefore, not part of the HATM model [9].  In addition, the HATM model 
assumes first order kinetics, which provides simplification of the process but provides an accurate 
representation of the mean residence time of a radionuclide in each element of the tract.  Each 
parameter in the model is represented by a transfer coefficient, which describes the outflow rate of a 
material from a compartment. The transfer coefficient is described as the instantaneous fraction of the 
contained material leaving the compartment per unit time.  Parameters used in the model may be 
generic values or element specific values.  Generic values refer to values that describe bulk flow of 
material through the lumen of the alimentary tract [9]. These values are given in the form of age, 
gender, and material specific transit times.  The element specific values are those that describe 
retention in or on the tissue, absorption to blood, and secretion from systemic organs or blood into the 
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lumen of the tract.  Minimal element specific parameters are available and where not available, the 
coefficient is assumed to be zero [9].  
 
2.6.1. Transit Times 
Transit through the lumen of the tract depends on the compartment of concern.  The transfer of 
material from the oral cavity to the esophagus is represented by a single transit time that is dependent 
on the type of material entering the oral cavity [9]. Default times are available for liquids, solids, and 
total diet.  
 
The transfer of material from the esophagus to the stomach is described by two transfer rates. Most 
swallowed food reaches the stomach in a matter of a few seconds. However, there is evidence from 
studies of labeled material fed by mouth that a portion of swallowed food may take longer for 
clearance, usually within a few minutes but sometimes longer [9]. This longer retention time may also 
be present in the case of inhaled material transferred to the alimentary tract by mechanical transport. 
Each of the two components of transfer from the esophagus to the stomach is represented by a single 
transit time, which is dependent on the type of material  
 
Transfer from the stomach to the small intestine is represented by a single transit time that depends on 
the type of material entering the stomach.  Default transit times are provided for water or other non-
caloric liquids, caloric liquids, solids, and total diet.  After the small intestine, the transit time is assumed 
to be independent of the type of material that initially entered the alimentary tract [9]. In addition, 
transfer from the small intestine to the right colon as well as each following sequential transfer is 
represented by a single transit time.  
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Table 3: Transfer Coefficients from ICRP 100 for the HATM 
 
 
2.6.2 Absorbed Fraction 
ICRP 100 also updated the way absorbed fractions were determined for alpha  particles and electrons. 
For electrons, it was determined that the approach taken in ICRP 30 may lead to a substantial 
overestimation.  In most cases, the absorbed fraction for alpha particles will be zero based on the 
location of the sensitive cells. This is true for all isotopes of uranium. Absorbed fractions for electrons 
are based on geometric models and were calculated using MCNP General Purpose Monte Carlo Code. 
The absorbed fractions for electrons in each region of the alimentary tract can be found in Table F.1 in  
Annex F of ICRP 100 [9].   
 
2.6.3 Absorption, Retention, and Secretion of Radionuclides 
 
The dose delivered to regions of the alimentary tract depends on two main things, the rate of transfer 
through the lumen and the extent of the radionuclide’s absorption to the blood and distribution in other 
tissues. Certain regions of the alimentary tract account for a great amount of absorption with the main 
region being the small intestine [9]. Absorption refers to the process that leads to the transfer of 
radionuclides from the alimentary tract to the blood and then to other tissues in the body. With high 
levels of absorption in the small intestines, smaller doses are usually present in the large intestine. Since 
the alimentary tract is a route of excretion variable portions of certain radionuclides may pass through 
 
 
13 
 
the large intestine. Doses to regions of the alimentary tract may also arise from radionuclides carried in 
the blood or deposited in tissues after absorption.  Absorption depends on the chemical properties of 
the radionuclide as well as the specific form of the intake [9]. For example, cesium behaves similar to 
potassium and therefore will be rapidly absorbed.  Additional dose may result with retention of 
radionuclides on the tissues of the alimentary tract. This is of particular concern because there is 
evidence of retention in the small intestine.  
 
In general, the absorption of radionuclides occurs with nutrient absorption in the small intestine. 
Absorption may occur through two different processes. The first involves passive diffusion while the 
second is active transport through the single layer of epithelial cells lining the small intestine.  
Although a majority of absorption occurs within the small intestine there is evidence to suggest that 
absorption of some elements and their radioisotopes may occur in other regions of the alimentary tract.  
The other regions include the mouth, stomach, and colon [9]. The large intestine is known to absorb 
water and electrolytes such as sodium and chloride while the stomach absorbs highly lipid soluble 
substances. In addition, there is some evidence to suggest the absorption of some elements including 
iodine, copper, and mercury in the stomach.  
 
2.6.4 Details of the Colon 
 
The fraction of the alimentary tract extending from the caecum to the anus contains three regions: right 
colon, left colon, and rectosigmoid.  The right colon is defined as the caecum, ascending colon, and 
proximal half of the transverse colon. The left colon is the distal half of the transverse colon plus the 
descending colon . Finally, the rectosigmoid includes the sigmoid colon and the rectum [9]. This division 
of the colon differs from the previous model of the gastrointestinal tract but is a standard division for 
diagnostic and experimental examinations of colonic transit. In addition, considerable information is 
available on transit times through each of these three sections.  From ICRP Publication 100, the Task 
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Group concluded that the division of the large intestine into these segments allows for the best estimate 
of the time-dependent distribution of ingestion, inhalation, or secreted activity in the colon [9].  
 
Although the rectum serves mainly as a channel for conveying, it may also serve as a storage organ 
when the amount of material is too small to induce defecation or is not convenient leading to a large 
amount of material being stored. Therefore since the transit time for material in the rectum is difficult, 
the rectum is not considered as a separate compartment [9].  
 
2.7 ICRP 30 Metabolic Data for Uranium 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Metabolic model for uranium 
 
Figure 3 outlines the uranium metabolic model from ICRP 30 [10]. Based on numerous studies 
investigating the uptake of uranium to the blood, anywhere from 0.005 and 0.05 of the compound is 
absorbed. ICRP 30 assumes an f1 value of 0.002 for relatively insoluble compounds of uranium such as 
UF4, UO2, and U3O8  and water-soluble inorganic compounds of uranium, the f1 is taken to be 0.05 [10].  
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The retention and distribution of uranium in bone and kidney have been determined using post-mortem 
data as well as intake from normal dietary uranium.  It is assumed fractions 0.2 and 0.023 go to mineral 
bone and are retained with a half-life of 20 and 5000 days. In addition, fractions 0.12 and 0.00052 are 
assumed to go to the kidneys with half-lives of 6 and 1500 days, respectively. Finally, fractions 0.12 and 
0.00052 are assumed to go to all other tissues and are retained for 6 and 1500 days [10]. The remaining 
fraction of uranium entering the transfer compartment is assumed to go directly to excretion.  
 
 
2.8 ICRP 69 Uranium Systemic Model 
 
Due to updated available information on actinides, the ICRP 30 metabolic data for was updated in 1995 
in ICRP publication 60 to include additional compartments [11]. This general model for actinides was 
adapted for uranium in ICRP 69. The model is based on an age-specific biokinetic model for calcium like 
elements proposed by Leggett [12]. One difference between the proposed model by Leggett and the 
updated ICRP model is the inclusion of two liver compartments in the ICRP model for actinides [11].  
 
The model includes entrance of uranium into the blood compartment through the gastrointestinal tract 
as well as the respiratory tract. The blood is treated as a uniform mixed pool. The uranium model also 
includes a red blood cell compartment, which exchanges with the plasma. As mentioned, the liver is 
separated into two compartments, Liver 1 and Liver 2. Liver 1 is considered the transit compartment and 
has a short retention time. Liver 2 is considered the storage compartment and has a long retention time 
(T1/2> 1 year).  Soft tissues, excluding liver and kidneys, are divided into three different compartments, 
slow, intermediate, and fast return of activity to the plasma. These compartments are labeled ST2, ST1, 
and ST0 in the ICRP 69 biokinetic model. ST0 includes extracellular fluids and transfers material over 
hours or days. This compartment serves two purposes, to represent early build up and decline of 
material as well as to account for early feedback into the blood. On the other hand, compartment ST1 
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represents intermediate retention, up to 2 years and ST2 represents long-term retention, for many 
years. Both compartments represent “massive soft tissue” including muscle, skin, and subcutaneous fat.  
The bone is broken down into cortical surface, cortical volume, exchange and non-exchange, trabecular 
surface, and trabecular volume, exchange and non-exchange.  Activity transferring from the bone 
surface to the bone volume, is assumed to enter the exchange compartment where it is removed to 
either the non-exchange volume or to the blood system with an element specific half-time. From the 
non-exchange volume, material is assumed to be removed to plasma by bone resorption [11]. For 
dosimetry purposes it is assumed that activity is evenly distributed in the bone volume, exchange and 
non-exchange. In addition, bone marrow is considered as part of other soft tissues.  In the case of 
excretion, activity is assumed to go directly to urine from the plasma and the gastrointestinal tract for 
feces. The additional compartment in the kidneys represents the retention in the renal tubes before 
excretion. Figure 4 displays the uranium systemic model from ICRP 69 [11].  
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Figure 4: ICRP 69 systemic system biokinetic model for uranium 
 
Table 4 displays the transfer coefficients for the ICRP 69 uranium systemic model. 
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Table 4: ICRP 69 transfer coefficients for the uranium systemic model 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.9 Gastrointestinal Procedures  
 
There is an increasing number of patients who undergo surgery on their GI tract for various reason 
including cancer, Crohns disease, as well as other medical conditions. These surgeries result in a change 
in pathway for an ingested radionuclide.  According to United Ostomy Association of America, 750,000 
ICRP 69 Uranium Systemic System Transfer Coefficients  
Path Transfer Coefficient (s-1) 
From Plasma to:  
ST0 0.000121528 
RBC 2.83565E-06 
Urinary bladder contents 0.000178588 
Kidney 1 3.40278E-05 
Kidney 2 1.41204E-07 
Upper large intestines content 1.41204E-06 
Liver 1 4.24769E-06 
ST1 1.88657E-05 
ST2 8.50694E-07 
Trabecular bone surface 2.36111E-05 
Cortical bone surfaces 1.88657E-05 
  
To Plasma From:  
ST0 9.62963E-05 
RBC 4.0162E-06 
Kidney 2 4.39815E-09 
Liver 1 1.06481E-06 
Liver 2 2.19907E-09 
ST1 4.0162E-07 
ST2 2.19907E-10 
Bone surfaces 8.02083E-07 
Nonexch trabecular Bone Volume 5.70602E-09 
Nonexch cortical Bone Volume 9.50231E-10 
  
Kidney 1 to urinary bladder contents 1.14583E-06 
Liver 1 to liver 2 8.02083E-08 
Bone surfaces to exchangeable bone volume 8.02083E-07 
Exchangeable bone volume to bone surfaces 2.00231E-07 
Exchangeable bone volume to 
nonexchangeable volume 
6.68981E-08 
 
 
19 
 
are living with an ostomy and over 130,000 new life-saving ostomies occur in America every year [13]. 
An ostomy refers to a surgically created opening in the body for the discharge of wastes. When 
temporarily implemented, this allows time for the organ to heal. On the other hand, some ostomies may 
be permanent. There are two main types of ostomies performed each year that affect the GI tract, 
including colostomy and Ileostomy.  
 
2.9.1 Colostomy 
A colostomy requires bringing one end of the large intestine out through an opening made in the 
abdominal wall [13].  The large intestine is connected to the small intestine and consists of the two main 
sections, the colon and the rectum.  The small intestine is the primary area of nutrient digestion, 
including fats, protein, and carbohydrates, which are then absorbed into the blood vessels. The food 
that cannot be absorbed moves from the small intestine to the large intestine, or more specifically, the 
colon, where mainly water is absorbed from the waste. The waste is continuously stored in the colon 
until the next bowel movement where it will eventually make its way down to the rectum.  
 
As indicated in Figure 5, there are various colostomy types [14]. There are three main types of 
colostomies. The  ascending colostomy is performed in the ascending colon and allows a majority of the 
colon to rest.  A traverse colostomy, which affects the upper large intestine in the transverse colon,  like 
the ascending colostomy allows for the colon to rest but  allows a shorter segment of the colon to 
recover. The descending and sigmoid colostomies, which affect the lower large intestine and mainly 
allows for the rectum to heal [13].   
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Figure 5: Location in the large intestine for each type of colostomy 
 
The type of approach the surgeon takes depends on the other types of procedures that need to be 
performed.  In general, the incision is made in the middle of the abdomen and the bowel resection and 
repair is done as needed.  An incision is made in the abdomen wall.  Once the incision is made, one end 
of the healthy colon is brought through the opening, normally on the left side. The surgically created 
opening of the large intestine is referred to as the stoma [13]. The edge of the bowl are stitched to the 
skin of the opening creating a stoma.  On the outside of the opening a bag is placed called a stoma 
appliance. The bags allows for the collection of stool. The pouching systems may include a one or two-
piece system. The one piece system consists of a plastic bag for collection. The two-piece system 
includes a mounting plate and the collection pouch. The bag attaches to the skin barrier and is fit over 
the stoma [13]. The colostomy bag is attached with an adhesive. The bags are designed to be air and 
watertight but may become dislodged or loose overtime due to loss of adhesion.  Figure 6 displays an 
example of a colostomy bag [15]. 
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Figure 6: Colostomy collection bag 
 
If a person requires surgery on a portion of their large intestine, a colostomy provides short-term rest 
and allows for recovery [13].  Once the large intestine has recovered from surgery, the patient will have 
to undergo another surgery to reattach the ends of the large intestine. There are numerous reasons a 
person may have to undergo a colostomy. These range from infection of the abdomen, injury to the 
colon or rectum, blockage of the large bowel, rectal or colon cancer, or wounds in the perineum [13]. 
 
2.9.2 Descending and Sigmoid Colostomies 
A descending colostomy is located in the descending portion of the colon. This portion of the colon takes 
the waste down the left hand side of the abdomen as shown in Figure 5 [13]. In a similar fashion, a 
sigmoid colostomy is located in the bottom portion of the large intestine.   
 
2.2.3 Transverse Colostomy 
A transverse colostomy is located in the transverse colon, as seen in Figure 5 [13]. The transverse colon 
crosses the top of the abdomen.  There are two types of transverse colostomies, the loop colostomy 
where the entire loop of bowel brought to the skin surface and the end is opened to create a non-
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functioning end.  The second is a double barrel colostomy where the colon is divided into two stomas 
[13]. 
2.2.4 Ascending Colostomy 
As indicated in Figure 5, an ascending colostomy is located in the ascending colon [13]. This is an 
extension of the beginning of the large intestine to the right side of the abdomen.  This procedure 
results in only partial function of the colon. This type of procedure is rare and an Ileostomy is usually 
more appropriate [13].  
 
2.3 Ileostomy 
The ileum is the lowest portion of the small intestine. Therefore, an Ileostomy refers to the a procedure 
in which the surgeon creates an opening in the stomach wall and brings the end of the ileum through 
the opening and attaches it the skin to create the stoma [9]. Figure 7 shows the placement of an 
Ileostomy in the small intestine [13].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Location of Ileostomy 
 
From the image, it is evident that through an Ileostomy, both the colon and the rectum are removed 
from the pathway for exiting waste.  Like the other colostomies, ileostomies can be permanent or 
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temporary and varies between patients depending on the severity of the medical issue [13].  If an 
Ileostomy is temporary, this most likely means part of the colon has been removed but part of the 
rectum remains. This could result from surgery performed on part of the large intestine. The surgeon 
would perform an Ileostomy, allowing the large intestine to rest. When the Ileostomy is no longer 
required, another surgery is required to reattach the small intestine.  An Ileostomy is required long term 
if both the large intestine and rectum have been removed [13]. There are numerous reasons a person 
would require an Ileostomy including,  inflammatory bowel disease,  colon or rectal cancer, familial 
polyposis , birth defects, or an accident involving damage to the intestines [13].  The pouching system 
for an ileostomy is the same appliance used for a colostomy and is attached through adhesion.   
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3.0 Model Development 
 
3.1 MATLAB Simulink 
 
For this research, MATLAB Simulink is utilized to model each dosimetric system. MATLAB is a software 
for scientists and engineers to analyze data, develop algorithms, and create models [16]. The Simulink 
suite was included in the MATLAB student version 8.6.0.267246 (R2015b). Simulink is a block diagram 
setting that allows for modeling and simulating dynamic systems [16]. Simulink provides a graphical 
interface, predefined blocks as well as user defined blocks that can be combined to create a unique 
system. One of Simulink’s key features is the simulation engine with fixed step and variable-step ODE 
solvers. The solvers are numerical integration algorithms that compute the system dynamics over time 
using the information contained within the model [16]. The fixed step solver computes the time of the 
next simulation step by adding a fixed step to the current time.  A variable-step solver varies the step 
size based on the local error to achieve the specified tolerance [16]. With the availability of fixed step 
and variable-step solvers in Simulink and the customizable block diagram setting a series of ordinary 
differential equations can be solved sequentially.  
 
 
3.2 MATLAB Simulink Modeling 
 
With the use of Simulink, the determination of the distribution and exchange of a radionuclide and its 
daughters through the human body using a series of ordinary differential equations is possible. The 
setup of each compartment in the model was based on previous research performed by Hrychushko 
[17].With the use of Simulink modeling, the initial intake and model pathways can be easily altered to 
allow for varying simulations and dose determinations.  
 
For example, when looking at the transfer of material in the stomach compartment to the ULI from the 
ICRP 30 gastrointestinal tract model, shown in Figure 8.  
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Figure 8: Stomach compartment from 
ICRP 30 GI tract model 
 
The resulting differential equation, using Equation 3, for the activity as a function of time within the 
stomach is given by equation 8 [1]. 
 
    
𝑑
𝑑𝑡
𝑞𝑆𝑇 = −𝜆𝑆𝑇𝑞𝑆𝑇(𝑡) − 𝜆𝑅𝑞𝑆𝑇(𝑡) + 𝐼(𝑡)           (8) 
 
Where:  
 
 λST is the transfer coefficient of the stomach 
 
 λR is the radioactive decay constant of the radionuclide 
 
 qST(t) is the activity of the radionuclide ingested at time t in the stomach 
 
 I(t) is the rate of ingestion of activity of the radionuclide 
 
The integration over 50 years, solved using MATLAB Simulink’s variable step ODE solver, gives the total 
number of transformations in the stomach. Figure 9 displays the blocks used to determine the number 
of transformations in 50 years in the stomach compartment from the ICRP 30 GI tract model based on 
Equation 9. 
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Figure 9: Detail showing the blocks used to calculate transformations 
in 50 years in the stomach compartment 
 
The calculation of the contribution to dose from the presence of the daughter isotopes, where 
applicable, was included in the dose calculation since it improved the accuracy of the total dose to the 
ICRP reported values. For example, the activity of the daughter radionuclide in the stomach 
compartment is determined by Equation 9 [1].  
 
   
𝑑
𝑑𝑡
𝑞′(𝑡) = −𝜆𝑆𝑇𝑞𝑆𝑇
′ (𝑡) − 𝜆𝑅
′ 𝑞𝑆𝑇
′ (𝑡) + 𝜆𝑅
′ 𝑞𝑆𝑇(𝑡)           (9) 
 
Where  
 
 λ’R is the decay constant of the daughter radionuclide 
 
 q’ST (t) is the activity of the daughter in the stomach and q(t) is the activity of the immediate 
 parent 
 
Figure 10 displays the blocks used to calculate the number of transformations for the first daughter in 
the stomach compartment based on Equation 9.  
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Figure 10: Blocks used to calculated the number of transformations for the parent and 
first daughter in the stomach compartment 
  
Each compartment also included the calculation to determine the SEE. This calculation is based on 
Equation 2 and is given by Equation 10 [1].  
 
    𝑆𝐸𝐸(𝑆𝑇 ← 𝑆𝑇) =
𝑌𝑖𝐸𝑖𝐴𝐹(𝑆𝑇←𝑆𝑇)𝑖𝑄𝑖
𝑀𝑇
    (10) 
Where 
  Yi is the yield of radiations of time i per transformation 
 
 Ei is the energy of radiation I  
 
 AF is the absorbed fraction in the stomach from radiation i  
 
 MT is the mass of the target organ 
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 Qi is the quality factor of the radiation; Q is 20 for alpha particles and 1 for electrons 
 
 
For alpha particles and electrons the specific absorbed fraction (SAF) is given by equation 11 [1]. 
 
     𝑆𝐴𝐹 =
1
2𝑀𝑇
𝜈      (11) 
Where 𝒗 represents the degree to which the radiation penetrates the mucus and ranges between 0 and 
1.  The value of 𝒗 for electrons and alpha particles is 1 and 0.01, respectively [1].  The absorbed fraction 
is determined by the energy of the radiation for photons. Therefore, in order to determine the absorbed 
fraction for photons, a user defined Simulink function block was used to interpolate the values given in 
ICRP 23 with the target being the stomach wall and the source being the stomach contents. The organ 
dose was then determined by Equation 1. Figure 11 displays the blocks used to determine the number 
of transformations, SEE value, and organ dose for the stomach compartment.  
Figure 11: Details including the various blocks used in the stomach subsystem 
 
Figure 11 only displays the detail of the stomach but the same approach was applied to each organ in 
the biokinetic model. In order to simplify the display of each model each organ was represented by 
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creating a subsystem. A subsystem displays only the basic information including any blocks used for 
inputs into inports such as constants or functions.  It also displays outputs from the exports, represented 
by sinks. Sinks may include graphs or numerical displays. In the model, a subsystem represents a specific 
organ or tissue. This keeps blocks functionally related to one another together. Each subsystem can be 
connected through inports and exports to represent the exchange of a radionuclide from one 
compartment to the next.  
 
Figure 12 displays an example of a subsystem, the stomach compartment of the gastrointestinal tract 
model from ICRP 30.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Single subsystem, the stomach, from the ICRP 30 GI tract model 
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From the subsystem, the inports include the ingestion, uranium half-life, thorium half-life, protactinium 
half life, and the initial activity in the stomach. The values were input based on the properties of the 
uranium isotope of interest and its daughters. For example, constants were used for the half-lives and 
initial activity as inputs into the inports. On the other side, the exports include the transfer of material to 
the small intestine, the transformations for each radionuclide, Us, occurring in the stomach, and the 
organ dose. Exports can be used to output values, using sinks, or connect subsystems. For example, the 
export for transfer of material to the small intestine was connected to the inport on small intestine 
subsystem and the number of transformations were output using a display block.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: The four subsystems of the ICRP 30 GI tract model and how each inport and export connects 
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Figure 13 displays the four subsystems (stomach, SI, ULI, LLI) comprising the ICRP 30 GI tract model and 
how the inport and export of each subsystem can be connected to couple the differential equations 
described by each subsystem. 
 
3.3 Development of Baseline Model 
 
In order to perform analysis to determine the effects a gastrointestinal procedure may have on internal 
dosimetry, ICRP 30 gastrointestinal tract model, ICRP 30 metabolic data for uranium, ICRP 100 Human 
Alimentary Tract Model (HATM), and ICRP 69 uranium systemic model were modeled using Simulink in 
the same manner as described in Figures 9-13.  The ICRP 30 GI tract model was connected to the ICRP 30 
metabolic model for uranium and the ICRP 100 HATM and ICRP 69 uranium systemic  model were 
connected. The ICRP 30 GI tract model was used because it is currently used by the NRC for federal 
regulation. On the other hand, ICRP 100 HATM model and ICRP 69 uranium systemic model was used 
because they are the most up to date models of the GI tract and blood system due to the updated 
available information since the ICRP 30 model. 
 
Each model was used to determine the number of transformations, the SEE values, and organ equivalent 
dose. Using the organ equivalent doses and the tissue weighting factors from Table 1, the total body 
effective dose was determined for ingestion and injection pathways for each uranium isotope. The 
effective dose was determined using ICRP 26 tissue weighting factors for the ICRP 30 GI tract and ICRP 
30 uranium systemic model combination. The whole body effective dose was determined using two 
methods for the ICRP 100 HATM and ICRP 69 systemic system model combination. The tissue weighting 
factors from ICRP 60 and ICRP 103 were applied and compared. 
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An instantaneous ingestion of 1 Bq was modeled for each combination. Specific model configuration 
parameters values were input into the system and were held constant. This allowed for reproducibility. 
For example, the half-life for 238U is 4.47x109 years and the initial activity in each organ was assumed to 
be zero.  A variable-step type solver was utilized in each model.  The use of a variable-step type solver 
reduces the step size when the state of the model changes rapidly to increase the accuracy [16]. It was 
determined running a fixed step size had no effect on the final dose calculation and resulted in 
significantly longer run times. Therefore, the step size was set to auto. In addition, the default 
differential equation solver, ode45, was used in each model.  Ode45 is a MATLAB solver that uses a 
Runge-Kutta method for solving ordinary differential equations [16]. Finally, the relative and absolute 
tolerances were set to default as changing the tolerance to low values did not change the accuracy of 
the results. Simulink automatically sets the relative tolerance and absolute tolerance to 10-3 and 10-6, 
respectively [16]. 
 
3.4 Benchmarking the Baseline Model 
In order to validate each model was running as expected the values output from the model were 
compared to the ICRP 30 literature values [1]. The ICRP 30 GI tract model was connected with the model 
for ICRP 30 metabolic data for uranium. To achieve this, an instantaneous ingestion of 1 Bq was 
assumed to occur at time t=0 and was represented by a step function in the Simulink model. Table 5 
displays a comparison between the SEE values output by the Simulink model and the ICRP 30 literature 
values for 238U and its daughters, 234Th and 234mPa [1]. 
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Table 5: SEE values determined by the Simulink model and literature values from ICRP 30 
Specific Effective Energy (MeV per g per transformation) of U-238 
Target Organ U-238 Th-234 Pa-234m 
 
Simulink 
Model 
ICRP 30 
% 
Error 
Simulink 
Model 
ICRP 30 
% 
Error 
Simulink 
Model 
ICRP 30 
% 
Error 
ULI 1.9E-03 1.9E-03 0 1.3E-04 1.4E-04 7.14 1.7E-03 1.9E-03 10.53 
LLI 3.1E-03 3.1E-03 0 2.1E-04 2.2E-04 4.55 2.8E-03 3.0E-03 6.67 
Cortical Bone 7.0E-03 7.0E-03 0 7.7E-06 7.8E-06 1.28 9.8E-05 1.0E-04 2.00 
Trabecular 
Bone 
1.7E-02 1.7E-02 0 1.2E-05 1.3E-05 7.69 1.6E-04 1.7E-04 5.88 
Kidney 2.7E-01 2.8E-01 3.57 1.9E-04 2.0E-04 5.00 2.4E-03 2.7E-03 11.11 
 
Similarly, the number of nuclear transformations over 50 years per unit intake of 238U resulting from the 
Simulink model were compared to the ICRP literature values. The values for 238U, 234Th and 234mPa are 
displayed in Table 6 [1].  
Table 6: Number of nuclear transformations, Us, determined by the Simulink model and literature 
values from ICRP 30 
Number of Transformations Over 50 Years per Unit of Intake (Transformations/Bq) U-238 
Target Organ U-238 Th-234 Pa-234m 
 
Simulink 
Model 
ICRP 30 
% 
Error 
Simulink 
Model 
ICRP 30 
% 
Error 
Simulink 
Model 
ICRP 30 
% 
Error 
ULI 47900 47000 1.91 1034 990 4.4 1033 990 4.3 
LLI 86230 86000 0.27 4220 4200 0.5 4218 4200 0.4 
Cortical Bone 21888 22000 0.51 14880 21000 29.1 10312 21000 50.9 
Trabecular 
Bone 
5472 5500 0.51 3720 5300 29.8 2578 5300 51.4 
Kidney 374 370 1.08 167 230 27.4 115 230 50.0 
 
Finally, the committed dose equivalent values and weighted dose equivalent output from the ICRP 30 GI 
tract Simulink model were compared to the literature values in ICRP 30 for 238U. The values are displayed 
in Table 7 and Table 8, respectively [1].  
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Table 7: Committed dose equivalent for target organs resulting from the Simulink model and 
literature values from ICRP 30 for U-238 
Committed Dose Equivalent per Unit of Intake (Sv/Bq) U-238  
Target Organ Simulink Model ICRP 30 % Error 
ULI 1.49x10-8 1.50x10-8 0.67 
LLI 4.483x10-8 4.60x10-8 2.54 
Bone Surface 3.993x10-8 4.0x10-8 0.25 
Kidney 1.621x10-8 1.70x10-8 4.65 
 
Table 8: Effective Dose for target organs calculated by the Simulink model compared to the literature 
ICRP 30 values for U-238 
Effective Dose per Unit of Intake (Sv/Bq) U-238  
Target Organ Simulink Model ICRP 30 % Error 
ULI 8.94x10-10 8.7x10-10 2.76 
LLI 2.69x10-9 2.7x10-9 0.37 
Bone Surface 1.2x10-9 1.2x10-9 0 
Kidney 9.73x10-10 1.0-9 2.7 
 
The same benchmark procedure was performed for 233U, 234U, and 235U for the ICRP 30 model.  Tables 9-
14 display the committed dose equivalent and the effective dose for each target organ from the 
Simulink model as well as the literature values from ICRP 30 and the calculated percent error.  
Table 9: Committed Dose Equivalent for target organs calculated by the Simulink model compared to 
the literature ICRP 30 values for U-234 
 
Table 10: Effective Dose for target organs calculated by the Simulink model compared to the literature 
ICRP 30 values for U-234 
Effective Dose per Unit Intake (Sv/Bq) U-234 
Target organ Simulink Model ICRP 30 % Error 
ULI 9.93E-10 9.7E-10 2.37 
LLI 2.91E-09 3.0E-09 3.00 
Bone Surface 1.35E-09 1.4E-09 3.57 
Kidney 1.10E-09 1.1E-09 0.00 
 
Table 11: Committed Dose Equivalent for target organs calculated by the Simulink model compared 
to the literature ICRP 30 values for U-233 
Committed Dose Equivalent per Unit Intake (Sv/Bq) U-234 
Target organ Simulink Model ICRP 30 % Error 
ULI 1.66E-08 1.60E-08 3.44 
LLI 4.85E-08 4.90E-08 0.94 
Bone Surface 4.51E-08 4.50E-08 0.2 
Kidney 1.83E-08 1.90E-08 3.53 
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Committed Dose Equivalent per Unit Intake (Sv/Bq) U-233 
Target organ Simulink Model ICRP 30 % Error 
ULI 1.67E-08 1.60E-08 4.06 
LLI 4.88E-08 5.00E-08 2.32 
Bone Surface 4.54E-08 4.60E-08 1.26 
Kidney 1.85E-08 1.90E-08 2.89 
 
Table 12:Effective Dose for target organs calculated by the Simulink model compared to the 
literature ICRP 30 values for U-233 
 
 
Table 13: Committed Dose Equivalent for target organs calculated by the Simulink model compared to 
the literature ICRP 30 values for U-235 
Committed Dose Equivalent per Unit Intake (Sv/Bq) U-235 
Target organ Simulink Model ICRP 30 % Error 
ULI 1.72E-08 1.70E-08 1.12 
LLI 5.26E-08 5.20E-08 1.10 
Bone Surface 4.15E-08 4.20E-08 1.26 
Kidney 1.74E-08 1.70E-08 2.24 
 
Table 14: Effective Dose for target organs calculated by the Simulink model compared to the 
literature ICRP 30 values for U-235 
 
 
 
 
 
 
 
Effective Dose per Unit Intake (Sv/Bq) U-233 
Target organ Simulink Model ICRP 30 % Error 
ULI 9.99E-10 9.8E-10 1.94 
LLI 2.93E-09 3.0E-09 2.33 
Bone Surface 1.36E-09 1.4E-09 2.86 
Kidney 1.11E-09 1.1E-09 0.91 
Effective Dose per Unit Intake (Sv/Bq) U-235 
Target organ Simulink Model ICRP 30 % Error 
ULI 1.03E-09 1.00E-09 3.00 
LLI 3.15E-09 3.20E-09 1.56 
Bone Surface 1.24E-09 1.3E-09 4.62 
Kidney 1.04E-09 1.00E-09 4.00 
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 The ICRP 100 model could not be benchmarked for the alimentary tract because the ICRP has not 
released updated dose coefficients for uranium using the new model. However, ICRP 130 plans to 
update the uranium dose coefficients in a future publication, which are necessary for benchmarking the 
model. However, the systemic system, ICRP 69 used in conjunction with ICRP 100 HATM was 
benchmarked using the dose coefficients provided in ICRP 69 for 238U. ICRP 69 uses an f1 value of 0.02.    
Therefore, in order to benchmark the ICRP 69 uranium systemic model, an f1 value of 0.02 was used. 
Table 15 provides the committed dose equivalent from the Simulink model and the ICRP 69 literature 
values.  
Table 15: Committed Dose Equivalent for ICRP 69 uranium 
systemic model 
Committed Dose Equivalent ICRP 69 (Sv/Bq) for U-238 
 
Simulink Model ICRP 69 % Error 
Bone Surface 6.75E-07 7.10E-07 5.0 
Kidney 2.49E-07 2.50E-07 0.4 
Liver 9.37E-08 9.60E-08 2.4 
 
 
After each system was modeled in Simulink and benchmarked against the ICRP literature values for each 
uranium isotope, both models combinations were used to make alterations and analyzed for all 
gastrointestinal procedures.  
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4.0 Development of Modified Anatomy Models 
 
Radionuclides may enter the alimentary tract directly as a result of the ingestion or indirectly through 
inhalation for a person with unmodified anatomy.  However, when an ostomy patient enters the 
workforce following the procedure, a potential new entrance point exists. This could lead to an 
accidental injection of radioactive material through the stoma. To determine the potential impacts to 
ostomies workers exposed to unsealed radioactive material, three pathways will be examined.  The 
pathways include ingestion, injection and stoma contamination or skin contamination. For this work, 
injection refers to the entrance of material through the stoma, or hole created during a colostomy.   
 
For this work, inhalation is not considered as a pathway. While inhalation is a main intake pathway, 
inhalation is not considered due to the small fraction of material transferred to the GI tract. The small 
fraction of material transferred to the GI tract would result in little to no change in dose estimates 
compared to unmodified anatomy.  If significant changes occur in the ingestion pathway, the 
assumption can be re-examined.  
 
When looking at the internal dose received by a worker it is important to consider the organs that the 
ingested radionuclide passes through. For a normal healthy individual, the pathway would look similar 
to that seen in Figure 1 or Figure 2, where the ingested radionuclide of concern would enter the mouth 
and continue through the body from the stomach to the small intestine, small intestine to the large 
intestine and though to excretion. The ICRP dosimetric model of the gastrointestinal tract discussed in 
section 2 models this type of anatomy. However, in the case of an ostomy patient, this generic model 
and must be modified to reflect the anatomical changes that occur. In each of the colostomy cases, the 
ostomy will result in a truncated colon. Therefore, when implementing changes to the base model, a 
new transfer coefficient will have to be determined. This is dependent on the length of the colon. In 
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addition, for the ICRP 30 model, the mass of the content will have to be altered to reflect what is 
present in the colon. It is assumed the content of the colon is uniformly distributed.  
 
4.1 Adapting Models to Modified Anatomy  
For a healthy person, the length of an individual’s colon may vary depending on gender and age. 
Therefore, in order to use the models to simulate each gastrointestinal procedure, a few assumptions 
had to be made about the gastrointestinal system. The lengths are based on the average colon lengths 
for an adult human. The colon has a total length of 150 cm [18]. In addition, the following lengths of the 
various sections of the colon are given; the ascending colon, 20 cm, the transverse colon, 45 cm, 
descending colon, 30 cm, sigmoid colon, 45 cm, and the rectum, 10 cm [18]. 
 
 ICRP 30 assumes the ULI consists of the ascending colon and the transverse colon. In addition, the LLI 
consists of the descending colon, sigmoid colon, and rectum. Based on the listed lengths and the 
predetermined section breakup listed from ICRP 30, the total length of the ULI and LLI were determined. 
It was determined when using ICRP 30 GI tract model, that ULI had a total length of 65 cm and the LLI 
had a total length of 85 cm. For the ULI this included adding the length of the ascending colon, 20 cm, 
and the length of the transverse colon, 45 cm, to given 65 cm. In the case of the LLI this included adding 
the length of the descending colon, 30 cm, the sigmoid colon, 45 cm, and the rectum, 10 cm.  
 
ICRP 100 divides the colon into three sections instead of two. Therefore, the length of each 
compartment, right colon, left colon, and rectosigmoid colon were determined. ICRP 100 assumes the 
right colon consists of the ascending colon and the distal half of the transverse colon, the left colon 
consists of the distal half of the transverse colon and the descending colon, and the rectosigmoid colon, 
consist of the sigmoid colon and the rectum. Therefore, the base ICRP 100 HATM model assumed the 
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right colon had a length of 42.5 cm. This was determined adding the ascending colon, 20 cm, and half 
the transverse, 22.5 cm.  The left colon was determined to have a total length of 52.5 cm. This was 
determined by adding the length of the distal half of the transverse colon, 22.5 cm and the descending 
colon, 30 cm. Finally, the rectosigmoid colon had a total length of 55 cm.  This was determined by 
adding the length of the sigmoid colon, 45 cm, and the rectum, 10 cm.  
 
4.2 Transit Times  
It was determined the change in dose to the colon was not sensitive to the location of the colostomy 
and differed by less than 1%. Table displays the dose of a transverse colostomy at 25%, 50%, and 75% of 
the transverse colon. Since 75% was the location used for dose calculation, the percent difference 
between the dose from 75% was determined for 25% and 50%.  
Table 16: CDE in the ULI for a transverse colostomy at various locations 
Committed Dose Equivalent in the ULI for ICRP 30 for a Transverse Colon 
Organ Transverse 
(75%) 
Transverse 
(25%) 
% Difference 
from 75% 
Transverse 
(50%) 
% Difference 
from 75% 
ULI 1.451E-08 1.462E-08 0.76 1.46E-08 0.62 
 
While in reality, each colostomy case is different and can be located at any point in the colon, for 
purposes of this report, it was assumed that each procedure occurs at point halfway in the specified 
section of the colon with the exception of the transverse colostomy. In order to represent the location 
of the colostomy as accurately as possible, the transverse colostomy was assumed to be located at a 
point 75% along the transverse colon.  For example, in the case of the transverse colostomy, it was 
assumed to occur at 75% of the transverse colon or based on the length, at 33.75 cm. With this 
assumption, 17% of the ULI compartment would be removed as well as the LLI.  Therefore, a transverse 
colostomy results in 83% of the ULI compartment remaining after the procedure and the transfer 
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coefficient was scaled to reflect the change.  Table 16 displays the percentage of colon remaining for 
each procedure for the ICRP 30 and ICRP 100 model.  
Table 17: Percent colon remaining for each ostomy case for ICRP 30 
and ICRP 100 
Procedure 
% Colon Remaining 
ICRP 30 
% Colon Remaining 
ICRP 100 
Ascending 
Colostomy 
ULI (16%) RC (23.5%) 
Transverse 
Colostomy 
ULI (83%) LC (21%) 
Descending 
Colostomy 
LLI (17.5%) LC (71%) 
Sigmoid 
Colostomy 
LLI (61.5%) Rectosigmoid (41%) 
Ileostomy 
Small Intestine 
(100%) 
Small Intestine (100%) 
 
 
Using the ICRP reported transfer coefficients, the lengths of the colon sections, and the location of the 
colostomy, new transfer coefficients were determined for each gastrointestinal procedure. For example, 
in the case of the transverse colostomy when applied to the ICRP 30 model, the new transfer coefficient 
was determine by 
     𝜆𝑈𝐿𝐼 =
2.1𝑥10−5
0.83
= 2.57𝑥10−5  
1
𝑠
    (12) 
 
 Table 17 displays the new transfer coefficients calculated in reference to the ICRP 30 GI tract model for 
each colostomy case and ICRP 30 literature values [1].  
 
Table 18:Transfer Coefficients used to simulate each procedure in the ICRP 30 configuration model 
Procedure Transfer Coefficient (s-1) ICRP 30 Transfer Coeffcient (s-1) 
Ascending Colostomy 1.34x10-4 2.1x10-5 
Transverse Colostomy 2.57x10-5 2.1x10-5 
Descending Colostomy 6.61x10-5 1.157x10-5 
Sigmoid Colostomy 1.887x10-5 1.157x10-5 
Ileostomy 6.9x10-5 6.9x10-5 
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In the same manner, the transfer coefficients were calculated for each colostomy case for the use in the 
ICRP 100 HATM model using the ICRP 100 transfer coefficients and the percent of remaining colon found 
in Table 16. In the case of the transverse colostomy applied to ICRP 100 HATM, the transfer coefficient 
does not change due to the division of sections in the model. The right colon consists of the proximal 
half of the transverse colon, this including up to the location where the transverse colostomy occurs. 
Table 18 displays the new transfer coefficients calculated for each colostomy procedure in reference to 
the ICRP 100 HATM model as well as the literature ICRP 100 transfer coefficients [9]. 
 
Table 19: Transfer Coefficients used to simulate each procedure in the ICRP 100 configuration model 
Procedure Transfer Coefficient (s-1) ICRP 100 Transfer Coefficient  
Ascending colostomy 1.013x10-4 2.381x10-5 
Transverse colostomy 1.066x10-4 2.381x10-5 
Descending colostomy 3.33x10-5 2.381x10-5 
Sigmoid colostomy 5.82x10-5 2.381x10-5 
Ileostomy 6.9x10-5 2.381x10-5 
 
4.3 Ingestion Pathway  
 
Figure 14 displays an example of the modified ICRP 30 model to reflect a transverse colostomy. 
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Figure 14: Block diagram representing the transfer between 
compartments in the case of a transverse colostomy for the 
ICRP 30 configuration 
 
The radionuclide would follow the same pathway described in ICRP 30 model however, the transit time 
in Table 17 would be applied to λULI to reflect a shortened ULI. In the case of the transverse colon, it was 
determined that 65% of the ULI would remain following an ostomy. The contents would then excrete 
into the bag application. The same procedure was applied to each ostomy case, in which the new 
transfer coefficient was applied to the model to reflect the anatomical changes occurring for each and 
the percentage of remaining colon found in Table 16. Figure 15 displays the transverse colostomy 
applied to ICRP 100 HATM.  
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Figure 15: Block diagram representing the transfer between 
compartments in the case of a transverse colostomy for the ICRP 
100 configuration 
 
Like, ICRP 30, the radionuclide would follow the same pathway until it reaches the right colon in which 
the transit time would be modified. λRC would be replaced by the new transfer coefficient found in Table 
18. The same procedure can be applied for each ostomy case depending on the compartment in which 
anatomical changes would occur, thus representing a shorter transit time due to a shortened colon.  The 
percentages found in Table 16 can be used to reflect the modified pathway in which the radionuclide 
would follow for ingestion.  
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4.4 Injection Pathway 
 
The injection pathway assumed an activity of 1 Bq is instantaneously injected at t=0 through the stoma 
into the intestine. It was assumed the radionuclide was uniformly distributed throughout the section of 
the colon in which the injection occurred. Since it was assumed uniform distribution took place within 
the colon section, the same transit times from Table 17 can be used in the ICRP 30 model.  Figure 16 
displays the schematic diagram of the injection pathway for the ICRP 30 model in the case of a 
transverse colostomy.  
 
 
 
 
 
 
 
 
 
 
 
Figure 16: Injection pathway for a transverse colostomy for 
the ICRP 30 model 
 
The same procedure can be applied to each ostomy case depending on which section the colostomy 
occurs. The transit times from Table 18 can be applied to the ICRP 100 HATM model to reflect the 
anatomical changes made by each ostomy. Figure 17 displays the transverse colostomy applied to the 
ICRP 100 HATM model. 
 
 
 
 
 
 
 
 
ULI (83%) 
Injection Excretion 
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Figure 17: Schematic Diagram of the injection pathway for an 
ileostomy applied to the ICRP 100 model 
 
4.5 Stoma Contamination 
 
As part of the injection pathway, contamination to the stoma was considered. Using a similar 
methodology, the equation used by VARSKIN can be simplified and applied to the dose calculation for 
contamination to the stoma.  Equation 4 gives the beta dose. In general, skin dose resulting from an 
alpha emitter is zero due to the layer of dead skin cell present.  However, alpha dose must be 
considered in contamination to the stoma due to the ability of the alpha particles to penetrate the colon 
wall. The stoma consists of living tissue and does not have a layer of dead cells protecting it like skin 
does. The equation used to calculate the beta and alpha dose to stoma is given by equation 13.  
 
      𝐷 =
0.5 𝐸𝑌𝑖𝑄𝐴𝐹
𝑚
     (13) 
Where: 
 
 E is the energy of the radiation 
 
 Y is the branching ratio 
 
 AF is the fraction of energy absorbed by the medium 
 
 m is the mass of the target  
 
The mass of the target was determined using the continuous slowing down approximation range of the 
alpha and beta particles. Assuming a 10 cm2 area of tissue, the relationship between CSDA and mass is 
given by the following equation.  10 cm2 was considered based on regulations. 
 
Left Colon (21%) 
Injection Excretion 
 
 
46 
 
     𝑚 = 𝐶𝑆𝐷𝐴 𝑥 10 𝑐𝑚2     (14) 
 
The CSDA for each alpha particle and beta particle was determined using tables provided by the National 
Institute of Standards and Technology (NIST)[19]. In order to determine the energy dependent CSDA 
from the tables provided by NIST, MATLAB was used to interpolate the energy specific values. This was 
achieved by utilizing the interp1 function.  MATLAB’s interp1 function is a 1-D data interpolation 
function, which returns interpolated values at specific query points using linear interpolation [16]. It was 
determined muscle provided the best CSDA estimate based on the biological properties of the colon and 
small intestine.  Unlike skin dose in which alpha particles would provide zero dose due to the inability of 
the alpha particle to penetrate past the dead layer of cells, the colon does not provide shielding from 
alpha particles. It was also assumed the mucosa layer did not provide any shielding from the alpha 
particles. Therefore, they must be taken into consideration in the skin dose calculation. In order to 
determine the dose to the colon from each uranium isotope, the alpha and beta dose was calculated for 
each uranium isotope. The dose to the stoma was determined for an area of 10 cm2 based on 
regulation. For example, using equation 5, the dose due to the 4.038 MeV alpha for 1 Bq of activity of 
238U was determined. 
 
  𝐷 =
(4.038
𝑀𝑒𝑉
𝑑𝑖𝑠
)1 𝐵𝑞 (1.6𝑥10−13
𝐽
𝑀𝑒𝑉
)(0.00078)(1)
2(0.0027 
𝑔
𝑐𝑚2
)(0.001 
𝑘𝑔
𝑔
)(10 𝑐𝑚2)
= 9.17𝑥10−12
𝐽
𝑘𝑔
 (𝐺𝑦)  (15) 
 
 
Converting the dose from Gy to Sv per hour the equivalent dose per hour was determined.  
 
    𝐻 =
9.17𝑥10−12(20)
3600
= 2.55𝑥10−15
𝑆𝑣
ℎ𝑟
    (16) 
 
In the same manner, the equivalent dose was determined for each alpha particle emitted from 238U. The 
result was then summed for all alpha particles emitted by the parent and if the parent included a short-
lived daughter radionuclide, the radiation emitted by the daughter radionuclide was included.  For 
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example, the beta particles emitted by 231Th, the daughter radionuclide for 235U, were included in the 
dose calculation because the half-life of 231Th is 25.5 hours. The same process was repeated for all alpha 
particles and beta particles emitted for each specific uranium isotope, using the energy dependent 
CSDA.   
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5.0 Results 
 
5.1 Ingestion Results ICRP 30 Model 
 
Each combination, ICRP 30 GI tract model with ICRP 30 uranium systemic model and ICRP 100 HATM 
model with ICRP 69 uranium systemic model, were used to evaluate the internal dose due to ingestion, 
injection, and skin dose contamination for 233U, 234U, 235U, and 238U.  In addition, for each isotope, the 
new transfer coefficients and colon mass changes were applied to reflect the anatomical changes 
present after an Ileostomy, ascending, transverse, descending, and sigmoid colostomy. Tables 19-22 
display the internal dose calculated using ICRP 30 methodology for ingestion for 233U, 234U, 235U, and 238U, 
respectively.  The dash (-) indicated there was no dose to the organ.  
Table 20: Committed dose equivalent (CDE) and Committed Effective Dose Equivalent (CEDE) for each 
target organ per unit intake ingestion of 233U for each procedure case applied to the ICRP 30 
configuration 
Committed Dose Equivalent per Unit Intake Activity of U-233 Ingestion (Sv/Bq) 
Organ Baseline Sigmoid Descending Transverse Ascending Ileostomy 
Stomach 1.10E-09 1.10E-09 1.10E-09 1.10E-09 1.10E-09 1.10E-09 
Small Intestine 2.75E-09 2.75E-09 2.75E-09 2.75E-09 2.75E-09 2.75E-09 
ULI 1.67E-08 1.67E-08 1.67E-08 1.63E-08 1.62E-08 - 
LLI 4.88E-08 4.87E-08 4.89E-08 - - - 
Bone Surface 4.54E-08 4.54E-08 4.54E-08 4.54E-08 4.54E-08 4.54E-08 
Kidney 1.85E-08 1.85E-08 1.85E-08 1.85E-08 1.85E-08 1.85E-08 
CEDE 6.63E-09 6.62E-09 6.63E-09 3.68E-09 3.67E-09 2.70E-09 
 
Table 21: Committed dose equivalent (CDE) and Committed Effective Dose Equivalent (CEDE) for each 
target organ per unit intake ingestion of 234U for each procedure case applied to the ICRP 30 
configuration 
Committed Dose Equivalent per Unit Intake Activity of U-234 Ingestion (Sv/Bq) 
Organ Baseline Sigmoid Descending Transverse Ascending Ileostomy 
Stomach 1.09E-09 1.09E-09 1.09E-09 1.09E-09 1.09E-09 1.09E-09 
Small Intestine 2.73E-09 2.73E-09 2.73E-09 2.73E-09 2.73E-09 2.73E-09 
ULI 1.66E-08 1.66E-08 1.66E-08 1.62E-08 1.67E-08 - 
LLI 4.85E-08 4.84E-08 4.86E-08 - - - 
Bone Surface 4.51E-08 4.51E-08 4.51E-08 4.51E-08 4.51E-08 4.51E-08 
Kidney 1.83E-08 1.83E-08 1.83E-08 1.83E-08 1.83E-08 1.83E-08 
CEDE 6.59E-09 6.58E-09 6.59E-09 3.65E-09 3.68E-09 2.68E-09 
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Table 22: Committed dose equivalent (CDE) and Committed Effective Dose Equivalent (CEDE) for each 
target organ per unit intake ingestion of 235U for each procedure case applied to the ICRP 30 
configuration 
Committed Dose Equivalent per Unit Intake Activity of U-235 Ingestion (Sv/Bq) 
Organ Baseline Sigmoid Descending Transverse Ascending Ileostomy 
Stomach 1.12E-09 1.12E-09 1.12E-09 1.12E-09 1.12E-09 1.12E-09 
Small Intestine 2.83E-09 2.83E-09 2.83E-09 2.83E-09 2.83E-09 2.83E-09 
ULI 1.72E-08 1.72E-08 1.72E-08 1.40E-08 2.99E-09 - 
LLI 5.26E-08 3.44E-08 1.21E-08 - - - 
Bone Surface 4.15E-08 4.15E-08 4.15E-08 4.15E-08 4.15E-08 4.15E-08 
Kidney 1.74E-08 1.74E-08 1.74E-08 1.74E-08 1.74E-08 1.74E-08 
CEDE 6.71E-09 5.62E-09 4.28E-09 3.36E-09 2.70E-09 2.52E-09 
 
Table 23: Committed dose equivalent (CDE) and Committed Effective Dose Equivalent (CEDE) for each 
target organ per unit intake ingestion of 238U for each procedure case applied to the ICRP 30 
configuration  
Committed Dose Equivalent per Unit Intake Activity of U-238 Ingestion (Sv/Bq) 
Organ Baseline Sigmoid Descending Transverse Ascending Ileostomy 
Stomach 9.66E-10 9.66E-10 9.66E-10 9.66E-10 9.66E-10 9.66E-10 
Small Intestine 2.42E-09 2.42E-09 2.42E-09 2.42E-09 2.42E-09 2.42E-09 
ULI 1.49E-08 1.49E-08 1.49E-08 1.45E-08 1.48E-08 - 
LLI 4.48E-08 4.44E-08 4.40E-08 - - - 
Bone Surface 3.99E-08 3.99E-08 3.99E-08 3.99E-08 3.99E-08 3.99E-08 
Kidney 1.62E-08 1.62E-08 1.62E-08 1.62E-08 1.62E-08 1.62E-08 
CEDE 5.96E-09 5.93E-09 5.90E-09 3.24E-09 3.26E-09 2.37E-09 
 
5.2 Ingestion Pathway ICRP 100 Model 
 
Tables 23-26 display the committed equivalent dose calculated for each procedure for 233U, 234U, 235U, 
and 238U using the ICRP 100 HATM and ICRP systemic system methodology. The tables also provide the 
total body effective dose. The effective dose was calculated using two methods, ICRP 60 tissue 
weighting factors and the ICRP 103 tissue weighting factors, found in Table 1. These provide the two 
most up –to-date tissue weighting factors.  
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Table 24: Committed dose equivalent (CDE) and Committed Effective Dose Equivalent (CEDE) for each 
target organ per unit intake ingestion of 233U for each procedure case applied to the ICRP 100 
configuration 
Committed Dose Equivalent and Total Effective Dose per Unit Intake U-233 Ingestion (Sv/Bq) 
Organ Baseline Sigmoid Descending Transverse Ascending Ileostomy 
Bone 8.09E-08 8.09E-08 8.09E-08 8.09E-08 8.09E-08 8.09E-08 
Liver 1.13E-08 1.13E-08 1.13E-08 1.13E-08 1.13E-08 1.13E-08 
Kidney 3.01E-08 3.01E-08 3.01E-08 3.01E-08 3.01E-08 3.01E-08 
CEDE ICRP 60 1.52E-09 1.52E-09 1.52E-09 1.52E-09 1.52E-09 1.52E-09 
CEDE ICRP 103 1.54E-09 1.54E-09 1.54E-09 1.54E-09 1.54E-09 1.54E-09 
 
Table 25: Committed dose equivalent (CDE) and Committed Effective Dose Equivalent (CEDE) for 
each target organ per unit intake ingestion of 234U for each procedure case applied to the ICRP 100 
configuration  
Committed Dose Equivalent and Total Effective Dose per Unit Intake U-234 Ingestion (Sv/Bq) 
Organ Baseline Sigmoid Descending Transverse Ascending Ileostomy 
Bone 8.03E-08 8.03E-08 8.03E-08 8.03E-08 8.03E-08 8.03E-08 
Liver 1.12E-08 1.12E-08 1.12E-08 1.12E-08 1.12E-08 1.12E-08 
Kidney 2.99E-08 2.99E-08 2.99E-08 2.99E-08 2.99E-08 2.99E-08 
CEDE  ICRP 60 1.51E-09 1.51E-09 1.51E-09 1.51E-09 1.51E-09 1.51E-09 
CEDE ICRP 103 1.52E-09 1.52E-09 1.52E-09 1.52E-09 1.52E-09 1.52E-09 
 
Table 26: Committed dose equivalent (CDE) and Committed Effective Dose Equivalent (CEDE) for each 
target organ per unit intake ingestion of 235U for each procedure case applied to the ICRP 100 
configuration 
Committed Dose Equivalent and Total Effective Dose per Unit Intake U-235 Ingestion (Sv/Bq) 
Organ Baseline Sigmoid Descending Transverse Ascending  Ileostomy 
Oral Contents 1.14E-17 1.14E-17 1.14E-17 1.14E-17 1.14E-17 1.14E-17 
Esophagus 6.27E-17 6.27E-17 6.27E-17 6.27E-17 6.27E-17 6.27E-17 
Stomach 2.05E-14 2.05E-14 2.05E-14 2.05E-14 2.05E-14 2.05E-14 
Small Intestine 4.08E-14 4.08E-14 4.08E-14 4.08E-14 4.08E-14 4.08E-14 
Small Intestine Wall 2.21E-14 2.21E-14 2.21E-14 2.21E-14 2.21E-14 2.21E-14 
Right Colon 2.68E-14 2.68E-14 2.68E-14 2.68E-14 1.49E-14 - 
Left Colon 4.72E-14 4.72E-14 4.40E-14 1.89E-14 - - 
Rectosigmoid 2.07E-13 1.86E-13 - - - - 
Bone 6.83E-08 6.83E-08 6.83E-08 6.83E-08 6.83E-08 6.83E-08 
Liver 9.48E-09 9.48E-09 9.48E-09 9.48E-09 9.48E-09 9.48E-09 
Kidney 2.53E-08 2.53E-08 2.53E-08 2.53E-08 2.53E-08 2.53E-08 
CEDE ICRP 60 1.28E-09 1.28E-09 1.28E-09 1.28E-09 1.28E-09 1.28E-09 
CEDE ICRP 103 1.29E-09 1.29E-09 1.29E-09 1.29E-09 1.29E-09 1.29E-09 
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Table 27: Committed dose equivalent (CDE) and Committed Effective Dose Equivalent (CEDE) for each 
target organ per unit intake ingestion of 238U for each procedure case applied to the ICRP 100 
configuration 
Committed Dose Equivalent and Total Effective Dose per Unit Intake U-238 Ingestion (Sv/Bq) 
Organ Baseline Sigmoid Descending Transverse Ascending Ileostomy 
Oral Contents 1.31E-17 1.31E-17 1.31E-17 1.31E-17 1.31E-17 1.31E-17 
Esophagus 7.19E-18 7.19E-18 7.19E-18 7.19E-18 7.19E-18 7.19E-18 
Stomach 7.33E-15 7.33E-15 7.33E-15 7.33E-15 7.33E-15 7.33E-15 
Small Intestine 2.77E-14 2.77E-14 2.77E-14 2.77E-14 2.77E-14 2.77E-14 
Small Intestine Wall 7.73E-15 7.73E-15 7.73E-15 7.73E-15 7.73E-15 7.73E-15 
Right Colon 3.21E-13 3.21E-13 3.21E-13 3.21E-13 1.66E-13 - 
Left Colon 6.48E-13 6.48E-13 5.77E-13 2.32E-13 - - 
Rectosigmoid 3.24E-12 2.70E-12 - - - - 
Bone 7.17E-08 7.17E-08 7.17E-08 7.17E-08 7.17E-08 7.17E-08 
Liver 9.96E-09 9.96E-09 9.96E-09 9.96E-09 9.96E-09 9.96E-09 
Kidney 2.65E-08 2.65E-08 2.65E-08 2.65E-08 2.65E-08 2.65E-08 
CEDE ICRP 60 1.35E-09 1.35E-09 1.35E-09 1.35E-09 1.35E-09 1.35E-09 
CEDE ICRP 103 1.36E-09 1.36E-09 1.36E-09 1.36E-09 1.36E-09 1.36E-09 
 
5.3 Injection Pathway ICRP 30 Model 
 
Tables 27-30 provide the dose calculated using ICRP 30 methodology resulting from an injection through 
the stoma for each procedure for 233U, 234U, 235U, and 238U.  In addition, the each table lists the calculated 
total body effective dose. The effective dose was calculated using ICRP 26 tissue weighting factors.  
Table 28: Committed dose equivalent (CDE) and Committed Effective Dose Equivalent (CEDE) for each 
target organ per unit intake injection of 233U for each procedure case applied to the ICRP 30 
configuration 
Committed Dose Equivalent and Committed Effective Dose per Unit Intake Activity of U-233  
Injection (Sv/Bq) 
Organ Sigmoid Descending Transverse Ascending Ileostomy 
Small Intestine - - - - 2.75E-09 
ULI - - 1.63E-08 1.62E-08 - 
LLI 4.88E-08 4.90E-08 - - - 
Bone Surface - - - - 4.54E-08 
Kidney - - - - 1.85E-08 
CEDE 2.93E-09 2.94E-09 9.77E-10 9.73E-10 2.63E-09 
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Table 29: Committed dose equivalent (CDE) and Committed Effective Dose Equivalent (CEDE) for each  
target organ per unit intake injection of 234U for each procedure case applied to the ICRP 30 
configuration  
Committed Dose Equivalent and Committed Effective Dose per Unit Intake Activity of U-234 
Injection (Sv/Bq) 
Organ Sigmoid Descending Transverse Ascending Ileostomy 
Small Intestine - - - - 2.73E-09 
ULI - - 1.62E-08 1.67E-08 - 
LLI 4.85E-08 4.87E-08 - - - 
Bone Surface - - - - 4.51E-08 
Kidney - - - - 1.83E-08 
CEDE 2.91E-09 2.92E-09 9.71E-10 1.00E-09 2.62E-09 
 
Table 30: Committed dose equivalent (CDE) and Committed Effective Dose Equivalent (CEDE) for each 
target organ per unit intake injection of 235U for each procedure case applied to the ICRP 30 
configuration 
Committed Dose Equivalent and Committed Effective Dose per Unit Intake Activity of U-235  
Injection (Sv/Bq) 
Organ Sigmoid Descending Transverse Ascending Ileostomy 
Small Intestine - - - - 2.82E-09 
ULI - - 1.38E-08 2.66E-09 - 
LLI 3.22E-08 9.37E-09 - - - 
Bone Surface - - - - 4.15E-08 
Kidney - - - - 1.74E-08 
CEDE 1.93E-09 5.62E-10 8.25E-10 1.60E-10 2.46E-09 
 
Table 31: Committed dose equivalent (CDE) and Committed Effective Dose Equivalent (CEDE) for each 
target organ per unit intake injection of 238U for each procedure case applied to the ICRP 30 
configuration 
Committed Dose Equivalent and Committed Effective Dose per Unit Intake Activity of U-238 
Injection (Sv/Bq) 
Organ Sigmoid Descending Transverse Ascending Ileostomy 
Small Intestine - - - - 2.42E-09 
ULI - - 1.45E-08 1.47E-08 - 
LLI 4.36E-08 4.32E-08 - - - 
Bone Surface - - - - 3.99E-08 
Kidney - - - - 1.62E-08 
CEDE 2.61E-09 2.59E-09 8.68E-10 8.84E-10 2.32E-09 
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5.4 Injection Pathway ICRP 100 Model 
 
Tables 31-32 provides the dose calculated due to injection of 235U and 238U. Under ICRP 100 
methodology, no dose results to the colon from alpha particles. Therefore, 233U and 234U are not 
included because they do have short lived daughter radionuclides that emit beta particles. For the 
ileostomy, dose would result in the bone, liver, and kidney compartments but would be the same as if 
ingested because the fraction of material transferred to the blood system remains the same.  The tables 
also provide the total body effective dose. The effective dose was calculated using two methods, ICRP 60 
tissue weighting factors and the ICRP 103 tissue weighting factors. 
Table 32:Committed dose equivalent (CDE) and Committed Effective Dose Equivalent (CEDE) for each 
target organ per unit intake injection of 235U for each procedure case applied to the ICRP 100 
configuration  
Committed Dose Equivalent and Committed Effective Dose per Unit Intake U-235 Injection (Sv/Bq) 
Organ Sigmoid Descending Transverse Ascending Ileostomy 
Small Intestine - - - - 3.14E-14 
Small Intestine Wall - - - - 2.06E-14 
Right Colon - - - 6.09E-15 - 
Left Colon - 1.78E-14 3.30E-15 - - 
Rectosigmoid 3.89E-14 - - - - 
Bone - - - - 6.83E-08 
Liver - - - - 9.48E-09 
Kidney - - - - 2.53E-08 
CEDE ICRP 60 1.56E-15 7.14E-16 7.74E-16 2.43E-16 1.28E-09 
CEDE ICRP 103 1.56E-15 7.14E-16 7.74E-16 2.43E-16 1.29E-09 
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Table 33: Committed dose equivalent (CDE) and Committed Effective Dose Equivalent (CEDE) for each 
target organ per unit intake injection of 238U for each procedure case applied to the ICRP 100 
configuration  
Committed Dose Equivalent and Total Effective Dose per Unit Intake U-238 Injection (Sv/Bq) 
Organ Sigmoid Descending Transverse Ascending Ileostomy 
Small Intestine - - - - 2.13E-14 
Small Intestine Wall - - - - 7.18E-15 
Right Colon - - - 5.77E-14 - 
Left Colon - 1.94E-13 3.14E-14 - - 
Rectosigmoid 3.97E-13 - - - - 
Bone - - - - 7.17E-08 
Liver - - - - 9.96E-09 
Kidney - - - - 2.65E-08 
CEDE  ICRP 60 1.59E-14 7.77E-15 8.97E-15 2.31E-15 1.35E-09 
CEDE  ICRP 103 1.59E-14 7.77E-15 8.97E-15 2.31E-15 1.36E-09 
 
5.5 Annual Limit on Intake 
 
To determine the potential risk to ostomy patients working with radioactive material, the annual limit 
on intake was calculated for each uranium isotope and for each ostomy case. The ALI must be satisfied 
by both the committed effective dose equivalent (CEDE) less than 0.05 Sv per year and the committed 
dose equivalent (CDE) less than 0.5 Sv per year [1]. Therefore, the ALI is determined by the limiting 
value. Tables 33-36 display the ALI’s for ingestion and injection for the ICRP 30 and ICRP 100 HATM 
model configurations. The limiting organ is listed in the table where applicable, if the ALI is limited by 
the CEDE, no organ is listed.  
5.5.1 Annual Limit on Intake Ingestion 
 
Table 34: Annual limit on intake  (ALI) for ingestion using the ICRP 30 configuration in Bq 
 Base Model Sigmoid Descending Transverse Ascending Ileostomy 
U-233 7.54E+06 7.55E+06 7.54E+06 
1.10E+07 
(Bone surf) 
1.10E+07 
(Bone surf) 
1.10E+07 
(Bone surf) 
U-234 7.59E+06 7.60E+06 7.58E+06 
1.11E+07 
(Bone surf) 
1.11E+07 
(Bone surf) 
1.11E+07 
(Bone surf) 
U-235 7.45E+06 8.90E+06 1.17E+07 
1.21E+07 
(Bone surf) 
1.21E+07 
(Bone surf) 
1.21E+07 
(Bone surf) 
U-238 8.39E+06 8.43E+06 8.47E+06 
1.25E+07 
(Bone Surf) 
1.25E+07 
(Bone Surf) 
1.25E+07 
(Bone Surf) 
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Table 35: Annual limit on intake (ALI) for ingestion using the ICRP 100 configuration in Bq 
 Base Model Sigmoid Descending Transverse Ascending Ileostomy 
U-233 
6.18E+06 
(Bone surf) 
6.18E+06 
(Bone surf) 
6.18E+06 
(Bone surf) 
6.18E+06 
(Bone surf) 
6.18E+06 
(Bone surf) 
6.18E+06 
(Bone surf) 
U-234 
6.23E+06 
(Bone surf) 
6.23E+06 
(Bone surf) 
6.23E+06 
(Bone surf) 
6.23E+06 
(Bone surf) 
6.23E+06 
(Bone surf) 
6.23E+06 
(Bone surf) 
U-235 
7.32E+06 
(Bone surf) 
7.32E+06 
(Bone surf) 
7.32E+06 
(Bone surf) 
7.32E+06 
(Bone surf) 
7.32E+06 
(Bone surf) 
7.32E+06 
(Bone surf) 
U-238 
6.98E+06 
(Bone surf) 
6.98E+06 
(Bone surf) 
6.98E+06 
(Bone surf) 
6.98E+06 
(Bone surf) 
6.98E+06 
(Bone surf) 
6.98E+06 
(Bone surf) 
 
5.5.2 Annual Limit on Intake Injection 
 
Table 36: Annual limit on intake (ALI) for injection using the ICRP 30 
configuration in Bq 
 Sigmoid Descending Transverse Ascending Ileostomy 
U-233 
1.02E+07 
(LLI) 
1.02E+07 
(LLI) 
3.07E+07 
(ULI) 
3.08E+07 
(ULI) 
1.10E+07 
(Bone surf) 
U-234 
1.03E+07 
(LLI) 
1.03E+07 
(LLI) 
3.09E+07 
(ULI) 
3.00E+07 
(ULI) 
1.11E+07 
(Bone surf) 
U-235 
1.55E+07 
(LLI) 
5.34E+07 
(LLI) 
3.64E+07 
(ULI) 
1.88E+08 
(ULI) 
1.21E+07 
(Bone surf) 
U-238 
1.15E+07 
(LLI) 
1.16E+07 
(LLI) 
3.46E+07 
(ULI) 
3.39E+07 
(ULI) 
1.25E+07 
(Bone surf) 
 
Table 37: Annual limit on intake (ALI) for injection using the ICRP 100 
configuration in Bq 
 Sigmoid Descending Transverse Ascending Ileostomy 
U-233 - - - - 
6.18E+06 
(Bone surf) 
U-234 - - - - 
6.23E+06 
(Bone surf) 
U-235 
1.29E+13 
(RS) 
2.80E+13 
(LC) 
2.59E+13 
(RC) 
8.21E+13 
(RC) 
7.32E+06 
(Bone surf) 
U-238 
1.26E+12 
(RS) 
2.57E+12 
(LC) 
2.23E+12 
(RC) 
8.66E+12 
(RC) 
6.98E+06 
(Bone surf) 
 
Based on Tables 33- 36, the ALI for each isotope and each case either remains the same as the 
benchmarked case or has a greater ALI than the benchmarked case in the case of ingestion for both 
model configurations. In the case of injection, for the ICRP 30 model configuration, the ALI for all 
uranium isotopes are determined by the CDE which applies the dose of the limiting organ. All ALI for the 
injection pathway are less than the ingestion pathway. The ICRP 100 model configuration results in the 
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same CEDE and CDE values for all cases. One exception is the ileostomy, which results in the same ALI as 
the ingestion pathway and is limited by the CDE value.  
 
5.6 Stoma Contamination Dose 
 
Table 37 provides the dose per unit activity per hour in the event skin contamination occurs. 
 
Table 38: Calculated skin dose in Sv per hour per 
Bq for a 10 cm2 area for each uranium isotope 
 
 
  
 
 
 
 
The values listed in Table 38 can be used to determine the dose to the colon dependent on the isotope 
in order to further assess the contamination hazards. Table 39 displays dose to the stoma as a function 
of contact time.  
Table 39: Dose per Bq as a function of contact time for each uranium 
isotope 
 
Dose per Bq (Sv/Bq) 
Time (min) U-233 U-234 U-235 U-238 
15 2.93E-11 1.51E-11 1.43E-11 1.61E-11 
30 5.86E-11 3.02E-11 2.86E-11 3.21E-11 
45 8.78E-11 4.53E-11 4.30E-11 4.82E-11 
60 1.17E-10 6.03E-11 5.73E-11 6.42E-11 
75 1.46E-10 7.54E-11 7.16E-11 8.03E-11 
90 1.76E-10 9.05E-11 8.59E-11 9.63E-11 
105 2.05E-10 1.06E-10 1.00E-10 1.12E-10 
120 2.34E-10 1.21E-10 1.15E-10 1.28E-10 
 
In addition, Table 39 displays the activity required to reach 10% of the annual limit to any organ of 0.5 Sv 
per year in one hour. 
  
Dose per Bq per Hour per 10 cm2 (Sv per hour) 
U-233 1.17E-10 
U-234 6.03E-11 
U-235 5.73E-11 
U-238 6.42E-11 
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Table 40: Activity of uranium required to reach 10% of annual limit 
in one hour 
 Dose Per hour (Sv per Bq per hour) Activity (Bq) 
U-233 1.17E-10 4.27E+08 
U-234 6.03E-11 8.29E+08 
U-235 5.73E-11 8.73E+08 
U-238 6.42E-11 7.78E+08 
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6.0 Discussion 
 
As mentioned the chemical form of the radionuclide of concern may vary depending on the type of 
exposure. For example, occupational exposures may result from specific inorganic forms of 
radionuclides not present in the environment. It is important to note that the chemical form of the 
radionuclide is likely changed during the digestive process [9]. These changes in chemical form will 
determine the availability of the radionuclide for absorption and therefore the extent of uptake through 
the intestinal epithelium to the bloodstream. As mentioned, this report will look at relatively insoluble 
compounds with an f1 value of 0.002. By changing the f1 value to reflect a more soluble compound, the 
fraction of material transferred to the blood system would increase leading to an increase in dose to the 
organs within the systemic system but would not result in greater risk to the GI tract.  
 
6.1 Ingestion Model 30 
 
The dose resulting to each section of the colon does not significantly change regardless of an alteration 
to the colon. In the case of a descending colostomy 233U and 234U the dose increases slightly from the 
benchmarked case. This is not true of any other colostomy scenario where the dose decreases from the 
unaltered case. This is not true for 235U and 238U where all committed dose equivalents are less than the 
benchmarked case. However, while the committed dose equivalent increased slightly in the case of the 
descending colostomy, it was determined to be insignificant, as it only differed from the unaltered case 
by 0.16%. In addition, the slight increase in dose did not change the total body effective dose. The total 
body effective dose is the same or less than the dose recorded for the benchmarked model. This is true 
for all uranium isotopes analyzed. This is due to the slight increase in dose in the colon in which the 
colostomy would take place for the sigmoid and descending colostomy as well as the dose to the LLI 
being absent from  the transverse and ascending colostomy. In addition, the CEDE for the ileostomy is 
the lowest due to the radionuclide not passing through the ULI and LLI resulting in no dose for both 
compartments. 
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Table 41: CEDE doses for the ingestion using the ICRP 30 model configuration 
Committed Effective Dose Equivalent for Ingestion Pathway 
 Base Model Sigmoid Descending Transverse Ascending Ileostomy 
U-233 6.63E-09 6.62E-09 6.63E-09 3.68E-09 3.67E-09 2.70E-09 
U-234 6.59E-09 6.58E-09 6.59E-09 3.65E-09 3.68E-09 2.68E-09 
U-235 6.71E-09 5.62E-09 4.28E-09 3.36E-09 2.70E-09 2.52E-09 
U-238 5.96E-09 5.93E-09 5.90E-09 3.24E-09 3.26E-09 2.37E-09 
 
6.3 Injection Model 30 
 
In the case of an injection, the recorded dose occurred within the section of the colon the injection 
through the stoma would occur except in the case of the ileostomy. This is because transfer to the blood 
system only occurs within the small intestine in the ICRP 30 model. Therefore, an injection outside the 
region of the small intestine would result in no dose to the bone or kidney. Although transfer to the 
blood would occur in the case of an ileostomy, the fraction of material transferred is the same as the 
baseline model, f1= 0.002, and does not result in additional dose to the bone or kidney. From the tables, 
the total body effective dose is less than the dose for a 1 Bq ingestion. Therefore, when looking at the 
annual limit on intake, the ALI for the case of the injection would be greater than the ALI for ingestion of 
the radionuclide.  
 
Table 42: CEDE for the injection pathway using the ICRP 30 model 
configuration 
Committed Effective Dose Equivalent for Injection Pathway 
 Sigmoid Descending Transverse Ascending Ileostomy 
U-233 2.93E-09 2.94E-09 9.77E-10 9.73E-10 2.63E-09 
U-234 2.91E-09 2.92E-09 9.71E-10 1.00E-09 2.62E-09 
U-235 1.93E-09 5.62E-10 8.25E-10 1.60E-10 2.46E-09 
U-238 2.61E-09 2.59E-09 8.68E-10 8.84E-10 2.32E-09 
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6.2 Ingestion Model 100 
 
When comparing the data for the ICRP 100 HATM and ICRP 69 systemic model combination, the 
committed dose equivalent in the section of the colon in which the specific colostomy occurs is lower 
than the benchmarked equivalent dose. In all cases, the dose to the bone, liver, and kidney remains 
unchanged. This is due to the transfer value f1 not changing from the baseline model. While there is 
retention in the small intestine wall the fraction transferred to the blood system remains the same. Due 
to the way the absorbed fractions are handled for alpha particles in the alimentary tract in ICRP 100, 
alpha dose is negligible in the colon due to the location of the cancer inducing cells. The cancer 
susceptible cells are located at a depth beyond the penetration depth of the alpha particle. This results 
in a significantly lower dose equivalent in the ICRP 100 HATM model than ICRP 30.  This is especially 
apparent in the cases of 233U and 234U. The dose to all sections of the colon is negligible and the only 
recorded dose results from the transfer of material to the organs within the systemic system. In the 
other case of 235U and 238U, the dose in the colon is due purely to the beta emissions from the daughter 
isotopes. 
 
Due to the low equivalent doses in the alimentary tract and the most significant dose occurring in the 
bone compartment for uranium, the committed effective dose equivalent does not change for each 
procedure for each isotope. In addition, there is no significant difference in the total body effective dose 
when using the ICRP 60 methodology versus the ICRP 103 methodology. Table 42 displays the CEDE 
using ICRP 103 methodology because they are more conservative than the ICRP 60. 
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Table 43: CEDE values for ingestions using the ICRP 100 model configuration 
Committed Effective Dose Equivalent for Ingestion  
 Base Model Sigmoid Descending Transverse Ascending Ileostomy 
U-233 1.54E-09 1.54E-09 1.54E-09 1.54E-09 1.54E-09 1.54E-09 
U-234 1.52E-09 1.52E-09 1.52E-09 1.52E-09 1.52E-09 1.52E-09 
U-235 1.29E-09 1.29E-09 1.29E-09 1.29E-09 1.29E-09 1.29E-09 
U-238 1.36E-09 1.36E-09 1.36E-09 1.36E-09 1.36E-09 1.36E-09 
 
6.4 Injection Model 100 
 
Finally, when looking at the injection pathway, the resulting total body effective dose is significantly 
lower than the ingestion pathway with the exception of the ileostomy in which the effective dose is 
consistent with the ingestion pathway. This is due to the transfer of material to the blood system from 
the small intestine and no transfer from additional compartments in the alimentary tract for uranium. In 
all other cases, the material would enter the colon through the stoma and transfer out in the same 
manner as the ingestion pathway thus, resulting in no transfer to the blood system.  The injection 
pathway was insignificant for 233U and 234U due to each isotope and daughter emitting only alpha 
particles. The only dose that would result is the dose due to transfer through the blood system but 
would not be increased from the ingestion case due to the constant transfer fraction.  
Table 44: CEDE values for the injection pathway using ICRP 100 
Committed Effective Dose for Injection 
 Sigmoid Descending Transverse Ascending Ileostomy 
U-235 1.56E-15 7.14E-16 7.74E-16 2.43E-16 1.29E-09 
U-238 1.59E-14 7.77E-15 8.97E-15 2.31E-15 1.36E-09 
 
 
6.6 Stoma Dose  
 
The major question regarding skin contamination is what level of activity would prompt medical 
intervention. The decision should ultimately be left up to the treating physician but the decision should 
take dosimetry into consideration.  No definitive guidance exists, as every case is different [20]. The 
intervention required may range from washing the contaminated area to surgical excision. The NCRP 
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report suggests intervention when the dose to the skin exceeds one to ten times the annual limit [20]. 
Doses to the stoma can be calculated using Table 37.  The first step in any contamination case is 
decontamination, removing any visible fragments and irrigation using a saline solution followed by 
assessment of remaining activity using an appropriate detector [20]. Soap and water may also be used in 
decontaminating the stoma and surrounding area. Any required additional action may want to be 
performed by a medical professional . While it is important to consult a health physicist, based on the 
length of time required to reach a dose level of concern or the level of activity that would have to 
present, the chemical hazard of the contaminant would be of greater concern than the radiological 
concerns of uranium.  
 
6.7 Conclusions 
 
Both the ICRP 30 gastrointestinal tract connected to the ICRP 30 uranium systemic model and the ICRP 
100 HATM and ICRP 69 uranium systemic model resulted in the same conclusion for ingestion. The 
equivalent dose in the affected colon was reduced below the benchmarked value. This in turn, led to a 
reduced overall total effective dose for the ICRP 30 model for a transverse or ascending colostomy, and 
in the case of an ileostomy.  The total effective dose remained the same in the case of a sigmoid or 
descending colostomy.  Table 44 displays the CEDE values determined from the ingestion pathway for 
the ICRP 30 model. 
Table 45: CEDE values for the ingestion pathway using ICRP 30 model for each uranium 
isotope 
Committed Effective Dose Equivalent for Ingestion Pathway 
 
Base Model Sigmoid Descending Transverse Ascending Ileostomy 
U-233 6.63E-09 
6.62E-
09 
6.63E-09 3.68E-09 3.67E-09 2.70E-09 
U-234 6.59E-09 
6.58E-
09 
6.59E-09 3.65E-09 3.68E-09 2.68E-09 
U-235 6.71E-09 
5.62E-
09 
4.28E-09 3.36E-09 2.70E-09 2.52E-09 
U-238 5.96E-09 
5.93E-
09 
5.90E-09 3.24E-09 3.26E-09 2.37E-09 
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Due to the change in tissue weighting factors for the ICRP 60 and ICRP 103, the total effective dose 
remained the same in the ICRP 100 combination regardless of whether the colon was anatomically 
changed due to a colostomy or not. This is because the ALI is determined by the greatest intake of a 
radionuclide that satisfies a total effective dose less than 0.05 Sv or a committed dose equivalent less 
than 0.5 Sv.  In the case of ICRP 100 the bone is the limiting organ and since the dose does not change, 
the ALI remains constant. In addition, the ALI is the lowest in the baseline case for the ICRP 30 
combination and does not change in the case of the ICRP 100 combination.. 
 
Based on the data, the injection pathway does not pose an additional risk to an occupational worker in 
regard to uranium.  The ALI calculated for injection is equivalent or orders of magnitude greater than the 
ingestion pathway. Therefore, it does not require additional limits on the amount of activity in use. Since 
the small intestine is the only section in which a fraction of material is transferred the systemic system, 
the ileostomy is the only scenario in which material can be passed to the blood for both model 
combinations. This resulted in no additional dose to any section in the gastrointestinal tract or systemic 
system. Finally, when looking at the ALI for all cases of injection for the ICRP 30 model combination, the 
ALI is greater than the baseline case for all colostomies except the Ileostomy. In the case of the 
Ileostomy, the ALI is the same as the ingestion pathway.   
 
Due to the unique pathway, there is no base model or ICRP reported ALI’s for the injection pathway. 
However, the ALI for all cases of injection for the ICRP 100 combination is significantly greater than the 
base model ingestion pathway in all cases except for the ileostomy, which is the same as the ingestion 
case. Therefore, due to a decrease in equivalent doses and an increase in ALI’s, no additional 
precautions need to be taken in the event a worker enters the workforce with a colostomy when 
considering injection as an individual pathway.  
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Due to the possibility of the adhesion on the bag application becoming loose over time there is a 
possibility for the appliance to become dislodged, leading to the possibility of stoma contamination. 
Stoma contamination is also necessary in the event injection occurs. Although the dose per hour does 
not appear to be significant, alpha particles can penetrate the wall of the intestine due to the lack of 
shielding. Therefore, the potential dose to the skin of the intestine should be taken into account. 
However, when looking at the skin dose due to each uranium isotope, the dose received to the stoma 
per hour is low. Furthermore, the activity required to reach 10% of the annual limit in one hour is on the 
order of 108 Bq. Oftentimes, uranium is dissolved in an acid solution like nitric or sulfuric acid. Therefore, 
due to low dose rate, the chemical hazards would be of more concern than the radiological risks. 
 
Taking into account all three potential pathways, ingestion, injection, and stoma contamination; there is 
no additional risk to an ostomy patient working with uranium. Furthermore, additional precautions do 
not need to be taken for an ostomy patient working with uranium. This means additional guidance is not 
necessary for ostomy patients to reduce potential exposure. In addition, if contamination of the stoma 
does occur, the chemical hazards are a greater concern than the radiological hazards.  
 
6.7 Future Work 
 
This work focused on uranium as it is commonly used for actinide research. With the base models built 
for each ICRP biokinetic model, the research can be expanded in a number of ways. The systemic model 
designed by Leggett and published in ICRP 69 is the base model for all actinides. This is due to the 
similarity in biological behavior of actinides once incorporated inside the body. In order to apply the 
model to other actinides, the transfer coefficients are element specific and would need to be updated 
for the specific radionuclide. This research focused on different uranium isotopes and the transfer 
values were specific to the uranium. In order to get a better look at the effects a gastrointestinal tract 
operation that alters the standard anatomy may have on internal dosimetry, other radionuclides 
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commonly used should be looked at. This could include the other actinides such as plutonium, thorium, 
and americium. Skin contamination may be of greater risk for a gamma emitter like 137Cs.  It may also 
include radionuclides with unique transfer to the blood system from areas in the alimentary tract other 
than the small intestine. For example, there is some evidence to suggest iodine is absorbed in the 
stomach. While uranium gave a good indication that no additional restrictions should be placed on an 
individual with a colostomy who has reentered the workforce, it should not be assumed this is true for 
all radionuclides. Therefore, it would be beneficial to look at other radionuclides. In particular, the other 
actinides would be a simple addition, as it would require minimal changes to the already existing models 
but would provide a better understanding about the effects.   
 
In addition, ICRP plans to publish updated dose coefficients for uranium and therefore, in the future will 
allow the ICRP 100 HATM model to be benchmarked against the literature values. With the publication 
of 130, ICRP also plans to include updated bone dosimetry [1]. Both the ICRP 30 and ICRP 69 systemic 
model used ICRP 30 methodology for calculation of bone equivalent dose as it is currently the only 
methodology for bone dosimetry. With the updated methodology, the model can be updated with the 
new methodology for bone dosimetry. With the new updated bone dosimetry and uranium dose 
coefficients, the model would have to be benchmarked against the updated values. This will provide the 
most up to date calculation for the dose to bone. This is especially important for uranium, as the bone is 
the limiting dose. While, this will not change the outcome of the research due to the transfer of material 
to the blood system being constant, it will allow for the most up to date dose calculation for bone. In 
addition, with the ability to benchmark the model against published ICRP 130 values for uranium in the 
GI tract, it will also ensure the dose to the alimentary tract is up to date.  
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